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Abstract 
 
Objectives: To assess the effectiveness and safety of imiquimod for the treatment of AGW 
in non-immunocompromised adults. 
Methods: We searched the Cochrane STI Group Specialized Register, CENTRAL, 
MEDLINE, EMBASE, LILACS, among other sources. RCTs comparing the use of 
imiquimod with placebo, any other patient-applied or any other provider-administered 
treatment for the treatment of AGW in non-immunocompromised adults. Three review 
authors independently assessed trials for inclusion, extracted data and assessed risk of 
bias. We resolved any disagreements through consensus.  
Results: Ten RCTs (1734 participants) met our inclusion criteria of which six were funded 
by industry. We judged the risk of bias of the included trials as high. Six trials compared 
the use of imiquimod versus placebo.  
There was very low quality evidence that imiquimod was superior to placebo in achieving 
complete and partial regression (RR 4.03, 95% CI 2.03 to 7.99; RR 2.56, 95% CI 2.05 to 
3.20, respectively) and frequency of systemic adverse reactions (RR 0.91, 95% CI 0.63 to 
1.32) were imprecise.  
Two trials compared the use of imiquimod versus any other patient-applied treatment 
(podophyllotoxin and podophyllin). The estimated effects of imiquimod on complete 
regression (RR 1.09, 95% CI 0.80 to 1.48), partial regression (RR 0.77, 95% CI 0.40 to 
1.47), recurrence (RR 0.49, 95% CI 0.21 to 1.11) or the presence of local adverse reactions 
(RR 1.24, 95% CI 1.00 to 1.54) were imprecise (very low quality evidence).  
Two trials compared imiquimod with any other provider-administered treatment (ablative 
methods and cryotherapy). There was very low quality of evidence that imiquimod did not 
have a lower frequency of complete regression (RR 0.84, 95% CI 0.56 to 1.28).  
 Imiquimod for anogenital warts in non-immunocompromised 
adults (Review) 
 
Conclusions: The beneﬁts and harms of imiquimod compared with placebo should be 
regarded with caution due to the risk of bias, imprecision and inconsistency for many of the 
outcomes we assessed. 
Keywords: Randomized controlled trials (RCTs), Anogenital warts (AGW), Sexually 
Transmitted Infections (STI), Review, Meta-Analysis, Imiquimod. 
 
 
Resumen  
 
Objetivos: Evaluar la eficacia y seguridad del imiquimod para el tratamiento de condiloma 
acuminado (AGW) en adultos no inmunocomprometidos. 
Métodos: Se buscaron ensayos clínicos (RCTs) en el Registro Especializado del grupo 
Cochrane STI, CENTRAL, MEDLINE, EMBASE, LILACS, entre otros; que compararan el 
uso de imiquimod contra placebo, otro tratamiento aplicado por el paciente o administrado 
por el proveedor para el tratamiento de AGW en adultos no inmunocomprometidos. Tres 
autores evaluaron independientemente los estudios para incluir, extraer información y 
evaluar el riesgo de sesgo. El desacuerdo se resolvió por consenso. 
Resultados: Diéz RCTs (1734 participantes) cumplieron criterios de inclusión, de los 
cuales seis fueron financiados por la industria. El riesgo de sesgo de los estudios se valoró 
como alto.  
Seis estudios compararon imiquimod contra placebo. Hubo muy baja calidad de la 
evidencia sobre imiquimod superior a placebo; la estimación en regresión completa o 
parcial. (RR 4.03, 95% CI 2.03 a 7.99; RR 2.56, 95% CI 2.05 a 3.20, respectivamente) y 
reacciones adversas sistémicas (RR 0.91, 95% CI 0.63 a 1.32) fue imprecisa.  
Dos ensayos compararon imiquimod contra otro tratamiento administrado por el paciente 
(podofilotoxina y podofilina). El efecto estimado de imiquimod en regresión completa (RR 
1.09, 95% CI 0.80 a 1.48), regresión parcial (RR 0.77, 95% CI 0.40 a 1.47), recurrencia 
(RR 0.49, 95% CI 0.21 a 1.11) y reacción adversa local (RR 1.24, 95% CI 1.00 a 1.54) fue 
impreciso (muy baja calidad de la evidencia).  
Dos ensayos compararon imiquimod contra otro tratamiento administrado por el proveedor 
(métodos ablativos y crioterapia). Hubo muy baja calidad de la evidencia, con imiquimod 
no hubo menos frecuencia de regresión completa (RR 0.84, 95% CI 0.56 a 1.28). 
 XIII 
 
Conclusiones: La eficacia y seguridad del imiquimod comparado con placebo debería 
tomarse con precaución considerando el riesgo de sesgo, imprecisión e inconsistencia en 
la mayoría de los desenlaces evaluados. 
Palabras clave: Ensayo clínico, condiloma acuminado, infección de transmisión 
sexual (STI), revisión, metanálisis, imiquimod.  
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 Summary1 
 
Background 
30% of people with anogenital warts (AGW) have spontaneous regression of lesions but 
there is no way to determine whether a speciﬁc lesion will remain. There are a wide range 
of options available for treating people with AGW and selection is based on clinician’s 
experience, patient preferences and adverse effects. The imiquimod could offer the 
advantages of patient-applied therapies without incurring the limitations of provider-
administered treatments. 
Objectives 
To assess the effectiveness and safety of imiquimod for the treatment of AGW in non-
immunocompromised adults. 
Search methods 
We searched the Cochrane Sexually Transmitted Infections Group Specialized Register 
(15 April 2014), CENTRAL (1991 to 15 April 2014), MEDLINE (1946 to 15 April 2014), 
EMBASE (1947 to 15 April 2014), LILACS (1982 to 15 April 2014), World Health 
Organization International Clinical Trials Registry (ICTRP) (15 April 2014), 
ClinicalTrials.gov (15 April 2014), Web of Science (2001 to 15 April 2014) and OpenGrey 
(15 April 2014). We also handsearched conference proceedings, contacted trial authors 
and reviewed the reference lists of retrieved studies. 
Selection criteria 
Randomized controlled trials (RCTs) comparing the use of imiquimod with placebo, any 
other patient-applied or any other provider-administered treatment (excluding interferon 
                                               
 
1 This document has been published elsewhere as form of the review entitled Imiquimod for 
anogenital warts in non-immunocompromised adults, published in The Cochrane Library 2014, Issue 
11; available on: http://www.thecochranelibrary.com 
2  
 
and 5-ﬂuorouracil which are assessed in other Cochrane Reviews) for the treatment of 
AGW in non-immunocompromised adults. 
Data collection and analysis 
Three review authors independently assessed trials for inclusion, extracted data and 
assessed risk of bias. We resolved any disagreements through consensus. The quality of 
the evidence was assessed using the GRADE approach. 
Main results 
Ten RCTs (1734 participants) met our inclusion criteria of which six were funded by 
industry. We judged the risk of bias of the included trials as high. Six trials (1294 
participants) compared the use of imiquimod versus placebo. There was very low quality 
evidence that imiquimod was superior to placebo in achieving complete and partial 
regression (RR 4.03, 95% CI 2.03 to 7.99; RR 2.56, 95% CI 2.05 to 3.20, respectively). 
When compared with placebo, the effects of imiquimod on recurrence (RR 2.76, 95% CI 
0.70 to 10.91), appearance of new warts (RR 0.76, 95% CI 0.58 to 1.00) and frequency of 
systemic adverse reactions (RR 0.91, 95% CI 0.63 to 1.32) were imprecise. We 
downgraded the quality of evidence to low or very low. There was low quality evidence that 
imiquimod led to more local adverse reactions (RR 1.73, 95% CI 1.18 to 2.53) and pain (RR 
11.84, 95% CI 3.36 to 41.63). 
Two trials (105 participants) compared the use of imiquimod versus any other patient-
applied treatment (podophyllotoxin and podophyllin). The estimated effects of imiquimod 
on complete regression (RR 1.09, 95% CI 0.80 to 1.48), partial regression (RR 0.77, 95% 
CI 0.40 to 1.47), recurrence (RR 0.49, 95% CI 0.21 to 1.11) or the presence of local adverse 
reactions (RR 1.24, 95% CI 1.00 to 1.54) were imprecise (very low quality evidence). There 
was low quality evidence that systemic adverse reactions were less frequent with imiquimod 
(RR 0.30, 95% CI 0.09 to 0.98). 
Finally, two trials (335 participants) compared imiquimod with any other provider-
administered treatment (ablative methods and cryotherapy). There was very low quality of 
evidence that imiquimod did not have a lower frequency of complete regression (RR 0.84, 
95% CI 0.56 to 1.28). There was very low quality evidence that imiquimod led to a lower 
rate of recurrence during six-month followup (RR 0.24, 95% CI 0.10 to 0.56) but this did not 
translate in to a lower recurrence from six to 12 months (RR 0.71, 95% CI 0.40 to 1.25; very 
low quality evidence). There was very low quality evidence that imiquimod was associated 
with less pain (RR 0.30, 95% CI 0.17 to 0.54) and fewer local reactions (RR 0.55, 95% CI 
0.40 to 0.74). 
 3 
 
Authors’ conclusions 
The beneﬁts and harms of imiquimod compared with placebo should be regarded with 
caution due to the risk of bias, imprecision and inconsistency for many of the outcomes we 
assessed in this Cochrane Review. The evidence for many of the outcomes that show 
imiquimod and patient-applied treatment (podophyllotoxin or podophyllin) confer similar 
beneﬁts but fewer systematic reactions with the Imiquimod, is of low or very low quality. 
The quality of evidence for the outcomes assessing imiquimod and other provider-
administered treatment were of very low quality. 
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1. Background2 
1.1 Description of the condition 
Description of the condition Human papillomavirus (HPV) is an non-enveloped, 
doublestranded DNA virus with an eight kilobase pair-long genome, which is comprised of 
eight open reading frames that encode early and late genes involved in the expression of 
non-structural (early: E1, E2, E5, E6 and E7) and structural (late: L1 and L2) proteins during 
the viral life cycle. HPVs are classiﬁed as “types” based on their genetic similarities (Grillo-
Ardila 2008). Currently, 180 different HPV types have been classiﬁed, approximately 30 of 
which have been found to infect genital epithelia. They are named “oncogenic” or “high risk” 
when they are associated with genital organ cancers (e.g. HPV 16, 18, 31 to 37). The other 
types are named “non-oncogenic” or “lowrisk” and are associated with genital warts (HPV 
6 and 11) (Wiley 2002). 
HPV speciﬁcally infects and replicates in the lower levels of the stratiﬁed epithelium. The 
spectrum of the infection includes the acquisition of the virus without pathological changes 
at the cellular level to intraepithelial neoplasia (Mayeaux 2008). Dysplastic changes begin 
with minor cytological changes, such as koilocytes and warts, to malignant changes. The 
natural history of diseasegoes from spontaneous clearance of the virus, a few months after 
acquisition in some cases, to the development of carcinoma of the genital tract in other 
cases (Wiley 2002). Regarding genital warts,no studies speciﬁcally show the time and the 
percentage of virus clearance from lesions (Wiley 2002). 
Up to 75%of sexually-active adults have been exposed to the HPV virus (as detected by 
HPV antibodies) and around 15% to 20% of them carry the virus (detected as HPV DNA by 
polymerase chain reaction) (Garland 2002). An estimated 1% of sexually active adults have 
                                               
 
2 This document has been published elsewhere as form of the review entitled Imiquimod for 
anogenital warts in non-immunocompromised adults, published in The Cochrane Library 2014, Issue 
11; available on: http://www.thecochranelibrary.com 
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genital warts (Weinstock 2004). The incidence of genital HPV infections decreases with 
age. Thus, detection of HPV infection among older women is more likely to reﬂect persistent 
infection, whereas detection among younger women more often represents recently 
acquired and probably transient infection (Ho 1998). 
Anogenital warts (AGW) occur on the penis, scrotum, vagina, vulva, anus and perineal 
areas and inguinal folds; areas that are traumatized during intercourse. Condylomas may 
be solitary but generally comprise from ﬁve to more than 15 lesions of 1 mm to 10 mm 
diameter. Warts may coalesce into large plaques (von Krogh 2000). The warts can be 
macular or ﬂat, keratotic, pedunculated, and acuminate or cauliﬂower-shaped. Symptoms 
may include inﬂammation, pain, ﬁssuring, itching, bleeding or dyspareunia (von Krogh 
2000). Diagnoses of AGW are primarily clinical (Garland 2002) by visual examination 
supported by a magnifying glass if necessary; this is the only recommended test for 
diagnosis and cure evaluation (Maw 2000). The acetic acid test is not a speciﬁc test for 
HPV infection and it should not be used for screening; nor is a biopsy, with or without viral 
typing, recommended for patients with typical lesions (Kodner 2004; Mayeaux 2008) 
because it doesn’t modify the treatment of the condition (von Krogh 2000). 
The differential diagnosis includes pearly penile papules and vulvars papillomatosis (normal 
variants), condyloma latum, seborrheic keratoses, dysplastic and benign nevi, molluscum 
contagiosum and neoplasms (Mayeaux 2008). 
1.2 Description of the intervention  
Although 30%of AGWspontaneously regress without treatment, there is no way to 
determine whether a speciﬁc lesion will regress, remain unchanged or increase in size 
(Berman 2012). Treatment should be offered to all patients with AGW (Workowski 2010). 
There are several treatments available for the management of genital warts. The treatment 
aims to reduce symptoms and visible lesions, but doesn’t eliminate HPV infection directly. 
Therapies such as interferon (IFN) and imiquimod treat the infection by stimulating immune 
responses (Dockrell 2001); the catechins has been involved in the regression of genital 
warts through the cell cycle arrest, apoptosis induction and the inhibition of HPV gene 
expression (Stockﬂeth 2012). In addition, cidofovir, an acyclic nucleoside phosphonate, 
directly affects viral replication and has been tested for treatment of HPV lesions (Ho 1998).  
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Treatment should be guided by the morphology, size, number and localization of the wart 
(Kodner 2004). Treatments are divided into provider and patient-applied therapy groups. 
Also, there are surgical and medical managements. Surgical treatments include 
electrosurgery, surgical excision, cryotherapy and laser surgery. Nonsurgical therapies, 
such as podophyllin, IFN and bi- and trichloroacetic acid (BCA, TCA) can be provider-
applied. Patientapplied medications include podophyllotoxin, imiquimod, catechins and 5-
ﬂuorouracil (5-FU) cream (Ho 1998; Workowski 2010). Imiquimod is indicated for the 
treatment of external AGW, superﬁcial basal cell carcinoma and actinic keratoses (Wagstaff 
2007). It has the potential to treat other HPV-associated conditions such as ﬂat warts, 
plantar warts and common warts (Verruca vulgaris) (Marini 2002).  
Imiquimod is used topically in cream form, with concentrations from 1% to 5%, by 
application daily or three times per week for eight to 16 weeks. Patients must be advised to 
wash the affected area with soap and water six to 10 hours after the application (Garland 
2002; Weinstock 2004). Systemic absorption is minimal (Miller 1999b). The drug is retained 
in the skin for prolonged periods, resulting in an elimination half-life of one day. Imiquimod 
and its active metabolites (S26704 and S27700) are excreted in urine and faeces (Wagstaff 
2007).  
Application of imiquimod can produce local skin reactions; the most frequent ones are local 
pruritus, erythema, excoriation or ﬂaking, erosion, edema, and scabbing or crusting. 
Systemic adverse events are rare and include headache, fatigue, myalgia and nausea. 
Other adverse events are decreases in hemoglobin, white blood cells and platelets. 
Reactions have been reported in skin at distant sites, such as erythema multiform, Steven 
Johnson syndrome and cutaneous lupus erythematosus (Wagstaff 2007). 
1.3 How the intervention might work 
Imiquimod is a novel synthetic imidazoquinoline (1-[2-methylpropyl]-1H-imidazo[4,5-
c]quinolin-4-amine) (Marini 2002). HPV is non-cytolytic, has no systemic phase and its 
replication is not accompanied by inﬂammation (Garland 2002) with the consequent 
evasion of antigen presentation, delaying the immune system activation. The clinical 
efﬁcacy of topical imiquimod is secondary to the stimulation of both innate and cell-
mediated immune responses to tumour and viral antigens (Dockrell 2001). The monocytes, 
keratinocytes, Langerhan’s cells and T-lymphocytes are stimulated to produce cytokines 
(INF-α and IL 1, 6, 8, 10 and 12); also B-lymphocytes proliferate to produce 
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immunoglobulins (Dockrell 2001). This drug produce inhibition of associated pathological 
angiogenesis via stimulated apoptosis (Buck 1998; Schön 2007). 
1.4 Why it is important to do this review 
Currently, there are a wide range of therapies available for people with AGW (Workowski 
2010). Choice is based on the experience of the healthcare provider, patient preference, 
cost of treatment, adverse effects and the feasibility of a given procedure (Maw2004), in 
addition to the absence of deﬁnitive evidence which shows which therapy is superior 
(Workowski 2010). 
Traditionally, patient-applied treatment, such as podoﬁlox and catechins (green tea), is 
frequently associated with local reactions like irritation, induration, erosion, pruritus, pain 
and edema. Provideradministered treatments (BCA, TCA, cryotherapy and surgical 
removal) require substantial clinical training, additional equipment, local or general 
anesthesia and longer ofﬁce visits with some risk of systemic absorption and toxicity 
(Workowski 2010), all of which limit applicability in clinical practice. 
In the USA and Europe, imiquimod is indicated for treatment of people with external genital 
and perianal warts and its efﬁcacy in immunocompetent patients has been assessed in 
several studies. Complete clearance of the warts occurred in 40% to 70% of imiquimod 
recipients after application three-times weekly or daily for eight to 16 weeks. Imiquimod has 
also been used in superﬁcial basal cell carcinoma, demonstrating superiority to placebo, 
with complete resolution of lesions in 79% to 87% of patients (Wagstaff 2007).  
Currently, there are no systematic reviews comparing the effectiveness and safety of 
imiquimod with other available therapies for treating AGW in non-immunocompromised 
adults. Imiquimod could offer the advantages of patient-applied therapies with a low local 
reaction rate, without incurring the limitations of provider-administered treatments. Thus it 
is necessary to assess the effectiveness and safety of imiquimod for treating AGW in non-
immunocompromised adults. Interferon (Chen 2009) and 5-FU (Batista 2010) are also 
considered treatments for AGW but are assessed separately in other Cochrane Reviews. 
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2. Methods3 
2.1 Criteria for considering studies for this review 
2.1.1 Types of studies 
Randomized controlled clinical trials, published and unpublished, comparing imiquimod as 
ﬁrst-line therapy with placebo, expectant management, any other patient-applied treatment 
or any other provider-administered therapy for the treatment of AGWin 
nonimmunocompromised adults. We excluded quasi-randomized trials because this 
produce effects estimates that indicate more extreme beneﬁts when they are compared 
with randomized clinical trials (Higgins 2011). Also we excluded cross-over trials because 
the carry over effect (Higgins 2011). 
2.1.2 Types of participants  
Men and non-pregnant women with immunocompetence, aged over 16 years and clinically 
diagnosed with AGW regardless of biopsy conﬁrmation. We excluded participants that did 
not have clinically visible lesions. 
2.1.3 Types of interventions 
Imiquimod treatment (of any concentration, frequency and dura-tion) versus: 
 placebo; 
 expectant management; 
 any other patient-applied treatment such as podoﬁlox or catechins (any 
concentration, frequency and duration of treatment); or 
                                               
 
3 This document has been published elsewhere as form of the review entitled Imiquimod for 
anogenital warts in non-immunocompromised adults, published in The Cochrane Library 2014, Issue 
11; available on: http://www.thecochranelibrary.com 
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 any other provider-administered treatment such as TCA, BCA, cryotherapy or 
surgical removal (any concentration, frequency and duration of treatment). 
We excluded interferon (Chen 2009) and 5-FU (Batista 2010) treatment as these have been 
assessed in other Cochrane Reviews. 
2.1.4 Types of outcome measures 
Primary outcomes  
1. Complete regression after treatment (total clearance of the warts). 
2. Partial regression after treatment (at least 50% clearance of he lesions). 
3. Dyspareunia after treatment. 
Secondary outcomes 
1. Time to complete regression. 
2. Relief of symptoms during treatment. 
3. Recurrence during follow-up (from 0 to six months, and from six to 12 months) 
4. Appearance of new warts during treatment. 
5. Excessive scarring at application site (hypertrophic scar or keloid). 
6. Time to resumption of intercourse. 
7. Pain during therapy. 
8. Pigmentary changes at application site (hypo- or hyperpigmentation at the site of 
application). 
9. Any local adverse reactions during therapy (erythema, irritation, ulceration, erosion, 
edema, ﬂaking or induration). 
10. Any systemic adverse reactions during therapy (headache, fatigue, myalgia, nausea, 
decrease of hemoglobin or white blood cells or platelets, erythema multiform, Steven 
Johnson syndrome or cutaneous lupus erythematosus). 
11. Requirement of any additional patient-applied or provider-administered treatment at the 
end of the therapy. 
12. Patient’s satisfaction with treatment. 
13. Cost effectiveness of imiquimod. 
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2.2 Search methods for identification of studies 
We attempted to identify as many relevant randomized controlled trials (RCTs) as possible 
of “imiquimod” for “anogenital warts”, irrespective of language of publication, publication 
date and publication status (published, unpublished, in press and in progress). We used 
both electronic searching in bibliographic databases and handsearching, as described in 
the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).  
2.2.1 Electronic searches 
We contacted the Trials Search Coordinator (TSC) of the Cochrane Sexually Transmitted 
Infections Group in order to implement a comprehensive search strategy to identify as many 
relevant RCTs as possible in electronic databases. We used a combination of controlled 
vocabulary (MeSH, Emtree, DeCS, including exploded terms) and free-text terms 
(considering spelling variants, synonyms, acronyms and truncation) for “anogenital warts” 
and “imiquimod”, with ﬁeld labels, proximity operators and Boolean operators. We have 
listed our search strategies in Appendix 1. 
We searched the following electronic databases: 
 Cochrane Sexually Transmitted Infections Group Specialized Register (15 April 
2014). 
 Cochrane Central Register of Controlled Trials (CENTRAL), Ovid platform (1991 to 
15 April 2014). 
 MEDLINE, Ovid platform (1946 to 15 April 2014). 
 MEDLINE In-Process & Other Non-Indexed Citations, Ovid platform (1946 to 15 
April 2014). 
 MEDLINE Daily Update, Ovid platform (1946 to 15 April 2014). 
 EMBASE (1947 to 15 April 2014). 
 LILACS, IAHx interface (1982 to 15 April 2014). 
For MEDLINE, we used the Cochrane highly sensitive search strategy for identifying RCTs: 
sensitivity and precision maximizing version (2008 revision), Ovid format (Higgins 2011). 
We combined the LILACS search strategy with a RCTs ﬁlter of IAHx interface. 
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2.2.2 Searching other resources  
We searched the following resources for additional trials: 
1. Trial registers: 
 WHO International Clinical Trials Registry Platform ICTRP portal 
(http://apps.who.int/trialsearch/). 
 ClinicalTrials.gov (http://clinicaltrials.gov/). 
2. Web of Science® (2001 to 15 April 2014). 
3. System for Information on Grey Literature in Europe “OpenGrey” 
(http://www.opengrey.eu/): 1990, 1992, 1995, 1996 and 1997. 
4. We contacted the trial authors of all RCTs we identiﬁed by other methods. 
5. We contacted pharmaceutical companies producing imiquimod 
for AGW. 
6. We handsearched the following journals: Anatolian Journal of Obstetrics & Gynecology, 
Current Medical Literature Gynecology & Obstetrics, Current Obstetrics and Gynecology 
Reports, ISRN Obstetrics and Gynecology, Journal of South Asian Federation of Obstetrics 
& Gynecology, Obstetrics and Gynecology International, Obstetrics Gynaecology and 
Reproductive Medicine, and Sexual Science: the Newsletter of the Society for the Scientiﬁc 
Study of Sexuality and Sexualities. 
7. Also we handsearched conference proceeding abstracts of the following events: 
 The International Society for Sexually Transmitted Diseases Research (ISSTDR) 
(http://www.isstdr.org/): 2007, 2009 and 2011. 
 The British Association for Sexual Health and HIV (BASHH) 
(http://www.bashh.org/): 2004, 2006, 2007 and 2009. 
 International Congress on Infectious Diseases (ICID) (http://www.isid.org/): 2010 
and 2012. 
 The International Union against Sexually Transmitted infections (IUSTI) 
(http://www.iusti.org/): 2011 and 2012. 
 International Society for Infectious Diseases (ISID) (http://www.isid.org/): 2011. 
 International Meeting on Emerging Diseases and Surveillance (IMED) 
(http://www.isid.org/): 2007, 2009 and 2011. 
 Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 
(http://www.icaac.org/): 2011 and 2012. 
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 The International Federation of Gynecology and Obstetrics (FIGO) 
(http://www.ﬁgo2012.org/ home/): 2012. 
8. We handsearched within previous systematic reviews, within other relevant ublications 
on the same topic and the reference lists of all RCTs identiﬁed by other methods. 
2.3 Data collection and analysis 
2.3.1 Selection of studies 
Three review authors (CFGA, EAM and LCSD) independently assessed for inclusion all the 
titles and abstracts of records retrieved from the search strategy. The ﬁnal selection of trials 
for inclusion was undertaken independently by three review authors and we resolved any 
disagreements through discussion. 
2.3.2 Data extraction and management  
We designed a data extraction form which was pilot tested. Three review authors (CFGA, 
EAM and LCSD) independently extracted from the eligible trials. We discussed any 
disagreements regarding extracted data until we reached consensus. 
We extracted information on the following items: 
 Location of the trial and setting. 
 Trial design. 
 Power calculation performed. 
 Inclusion and exclusion criteria. 
 Baseline information of the participants in order to have comparable intervention 
groups at entry (number of women, number of men, site, size, number and shape 
of lesions, number of participants who received imiquimod as ﬁrst-line therapy or as 
second-line therapy). 
 Total number of intervention groups. 
 Types of interventions: imiquimod any concentration, frequency and duration of 
treatment. 
 Types of comparison: any patient-applied treatment (any concentration, frequency 
and duration of treatment) or any other provider-administered treatment (any 
concentration, frequency and duration of treatment). 
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 Number of subjects enrolled, randomized, excluded after randomization and 
analyzed. 
 Number of participants lost to follow-up in the groups. 
 Outcomes stated in methods versus outcomes reported in results. 
 How secondary outcomes were defined. 
 Differences between groups for outcome assessment. 
 Time of follow-up of participants for speciﬁc outcomes. 
 How adverse event reports were validated. 
 Funding sources reported. 
 Ethical issues: use of signed informed consent and ethics approval.  
We entered data into Review Manager (RevMan) and checked them for ensuring data 
quality. When information regarding any of the above was unclear, we contacted authors 
of the original reports for further details. For a single randomized controlled clinical trial 
report, we extracted data directly onto the data extraction form. In the case of multiple 
reports, we extracted data from each report separately and then combined them across the 
forms. 
2.3.3 Assessment of risk of bias in included studies  
Three review authors (CFGA, LCSD and EAM) independently assessed risk of bias for 
each included trial using the criteria outlined in the Cochrane Handbook for Systematic 
Reviews of Interventions (Higgins 2011). We resolved any disagreements by consensus or 
by involving a third review author (HGD). The review authors that assessed risk of bias 
were thematic and methodology experts. We assessed the following information which we 
used to complete the risk of bias tables. 
Random sequence generation (checking for possible selection 
bias) 
For each included trial we recorded the method used to generate the allocation sequence 
in sufﬁcient detail to allow an assessment of whether it should produce comparable groups. 
We assessed the method as: low risk of bias (any truly random process, e.g. random 
number table; computer random number generator); high risk of bias (any non-random 
process, e.g. odd or even date of birth; hospital or clinic record number); or unclear risk of 
bias. 
 17 
 
Allocation concealment (checking for possible selection bias) 
We determined the method used to conceal allocation to interventions prior to assignment 
and assessed whether intervention allocation could have been foreseen before or during 
recruitment, or changed after assignment. We assessed the methods as: low risk of bias 
(e.g. telephone or central randomization; consecutively numbered sealed opaque 
envelopes); high risk of bias (e.g. open random allocation; unsealed or non-opaque 
envelopes; alternation; assignment by date of birth); or unclear risk of bias. 
 Blinding of participants and personnel (checking for possible 
performance bias) 
We described for each included trial the methods used, if any, to blind trial participants and 
personnel from knowledge of which intervention a participant received. We considered that 
trials were at low risk of bias if no blinding or incomplete blinding, but we judged that the 
outcome is not likely to be inﬂuenced by lack of blinding or in case of blinding of participants 
and key study personnel, and unlikely that the blinding could have been broken. We 
considered that trials were at high risk of bias if no blinding or incomplete blinding, and the 
outcome is likely to be inﬂuenced by lack of blinding or blinding of key study participants 
and personnel attempted, but likely that the blinding could have been broken, and the 
outcome is likely to be inﬂuenced by lack of blinding. Finally, unclear risk of bias if the 
provided information was insufﬁcient to permit judgement of ‘Low risk’ or ‘High risk’. We 
assessed blinding separately for different outcomes or classes of outcomes. 
 Blinding of outcomes assessment (checking for possible 
detection bias) 
For each included trial we noted the methods used, if any, to blind outcome assessors 
fromknowledge of which intervention a participant received. We assessed blinding 
separately for different outcomes or classes of outcomes. We assessed methods used to 
blind outcome assessment as low, high or unclear risk of bias. We considered that trials 
were at low risk of bias if no blinding of outcome assessment, but we judged that the 
outcome measurement is not likely to be inﬂuenced by lack of blinding or blinding of 
outcome assessment ensured, and unlikely that the blinding could have been broken. We 
considered that trials were at high risk of bias if no blinding of outcome assessment, and 
the outcome measurement is likely to be inﬂuenced by lack of blinding or blinding of 
outcome assessment, but likely that the blinding could have been broken, and the outcome 
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measurement is likely to be inﬂuenced by lack of blinding. Finally unclear risk of bias if the 
provided information was insufﬁcient to permit judgement of ‘Low risk’ or ‘High risk’. 
Incomplete outcome data (checking for possible attrition bias due 
to de amount, nature and handling of incomplete outcome data) 
We described for each included trial, and for each outcome or class of outcomes, the 
completeness of data including attrition and exclusions from the analysis. We stated 
whether trial authors reported attrition and exclusions and the numbers included in the 
analysis at each stage (compared with the total randomized participants), reasons for 
attrition or exclusion where reported, and whether missing data were balanced across 
groups or were related to outcomes. Where trial authors reported or supplied sufﬁcient 
information, we re-included missing data in the analyses we performed. We assessed 
methods as low risk of bias (e.g. no missing outcome data; missing outcome data balanced 
across groups); high risk of bias (e.g. numbers or reasons for missing data imbalanced 
across groups; ’as treated’ analysis done with substantial departure of intervention received 
from that assigned at randomization); or unclear risk of bias. We used a cut-off point of 20% 
to consider a trial was at low or high risk of bias according to the level of missing data. 
Selective reporting (checking for reporting bias) 
We investigated the possibility of selective outcome reporting bias in the included trials and 
reported what we found. We assessed the methods as: low risk of bias (where it was clear 
that all of the trial’s pre-speciﬁed outcomes and all expected outcomes of interest to the 
review were reported); high risk of bias (where not all the trial’s pre-speciﬁed outcomes 
were reported; one or more reported primary outcomes were not pre-speciﬁed; outcomes 
of interest were reported incompletely and so could not used; the trial failed to include 
results of a key outcome that would have been expected to have been reported); or unclear 
risk of bias. 
Other bias (checking for bias due to problems not covered by 
above) 
We noted any important concerns we had about other possible sources of bias (stopped 
early due to some data-dependent process or extreme baseline imbalance or has been 
claimed to have been fraudulent or have been sponsored by industry) (Higgins 2011). We 
assessed whether each trial was free of other problems that could have put it at risk of bias. 
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Overall risk of bias 
We made explicit judgements about whether trials were at high risk of bias, according to 
the criteria given in Higgins 2011. With reference to (1) to (6) above, we assessed the likely 
magnitude and direction of the bias and whether we considered it likely to impact on the 
ﬁndings. 
2.3.4 Measures of treatment effect 
Dichotomous data 
For dichotomous data, we presented the results as risk ratios (RRs) with 95% conﬁdence 
intervals (CIs). The RR is used as a relative effect measure, which works well with a low or 
high rate of events, and is easy to interpret and use in clinical practice. 
Continuous data 
For continuous data, we used the mean difference if outcomes were measured in the same 
way between trials. We used the standardized mean difference to combine trials that 
measured the same outcome but used different methods. 
2.3.5 Unit of analysis issues 
We determined which intervention groups were relevant in clinical trials that randomized 
participants to several intervention groups. In order to avoid confusion for the reader, we 
included all intervention groups of the trial in the Characteristics of included studies table in 
the notes cell, provided a detailed description only of the intervention groups relevant to 
this review and only used these groups in the analyses. 
In order to overcome a unit-of-analysis error for trials that contributed multiple, correlated 
comparisons, we used two approaches: we combined all relevant experimental intervention 
groups of the trials into a single group and also combined all relevant control intervention 
groups into a single control group so we could create a single pair-wise comparison 
(Higgins 2011) when the objective was to compare the experimental branch with any other 
control group (e.g. imiquimod versus placebo). However, when the objective was to detect 
differences between experimental groups (e.g. among different imiquimod concentrations), 
we split the sample of the control group in order to assess the respective comparison 
(Higgins 2011). 
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Based on the above, one 3-arm randomized clinical trial (Schofer 2006) compared ablation 
alone (Group A), imiquimod 5%cream monotherapy (Group B) and combined ablation 
followed by topical imiquimod (Group C). For the purpose of this systematic review, we only 
included the relevant experimental (B) and control intervention (A) group (Group A versus 
B), creating a single pair comparison. Finally, three trials compared two different doses of 
imiquimod versus vehicle cream, using 1% and 5% imiquimod (Beutner 1998; Edwards 
1998) or 2.5% and 3.75% imiquimod (Baker 2011). For these trials, we combined all 
relevant experimental intervention groups of the trials into a single group in order to create 
a single pair-wise comparison (Higgins 2011). However, when the target was to detect 
differences in the experimental groups (e.g. different imiquimod concentrations), we split 
the sample of the control group (vehicle cream) in order to determine the respective 
comparison (Higgins 2011). 
2.3.6 Dealing with missing data  
We identiﬁed levels of attrition for included trials and we per-formed analyses for all 
outcomes, as far as possible, on an intention-to-treat basis, i.e. we attempted to include all 
participants randomized to each group in the analyses, and all participants were analyzed 
in the group to which they were allocated, regardless of whether or not they received the 
allocated intervention. The denominator for each outcome in each trial was the number 
randomized minus any participants whose outcomes were known to be missing. We 
planned to explore the impact of including trials with high levels of missing data in the overall 
assessment of treatment effects by using sensitivity analysis but we did not have 
anadequate number of included trials. 
2.3.7 Assessment of heterogeneity 
We assessed statistical heterogeneity using the T², I² statistic and Chi² test. We regarded 
heterogeneity as substantial if the I² statistic value was > 40%, and either T² was greater 
than zero or P < 0.10 in the Chi² test for heterogeneity (Higgins 2011). 
2.3.8 Assessment of reporting biases 
We planned to explored publication bias through assessment of funnel plot asymmetry and 
formal tests. For continuous outcomes, we planned to use the test proposed by Egger 1997, 
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and for dichotomous outcomes we planned to use the test proposed by Harbord 2006. 
However, we included fewer than ten trials in the meta-analysis so we did not perform these 
analyses. 
2.3.9 Data synthesis 
We performed statistical analyses using Review Manager (RevMan). We used ﬁxed-effect 
meta-analysis for combining data where it was reasonable to assume that trials were 
estimating the same underlying treatment effect (i.e. where trials were examining the same 
intervention, and the trials’ populations and methods were judged sufﬁciently similar). If 
there was clinical heterogeneity sufﬁcient to expect that the underlying treatment effects 
differed between trials, or if we detected substantial statistical heterogeneity, we used 
random-effects meta-analysis to produce an overall summary if an average treatment effect 
across trials was considered clinically meaningful. We treated the random-effects summary 
as the average range of possible treatment effects and we discussed the clinical 
implications of treatment effects differing between trials. If the average treatment effect was 
not clinically meaningful we did not combine trials. Where we used random-effects 
analyses, we presented the results as the average treatment effect with 95% CIs, and the 
estimates of the T² and I² statistic. 
2.3.10 Subgroup analysis and investigation of heterogeneity  
We proposed to explore the following potential sources of heterogeneity using subgroup 
analyses: 
1. Concentration of imiquimod (less than 5%; 5% or more). 
2. Duration of therapy (12 weeks or less; or more than 12 weeks). 
3. Times per week (once daily; any other frequency per week). 
4. Lesion site (perineal, perianal or other skin site). 
5. Sex of the patient. 
6. Severity of the disease (area major or minor of 1 cm). 
We used the following outcomes in subgroup analyses: 
1. Complete regression after treatment. 
2. Partial regression at the end of the treatment. 
3. Dyspareunia after treatment. 
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For ﬁxed-effect inverse variance meta-analyses we assessed differences between 
subgroups by interaction tests. For random-effects and ﬁxed-effect meta-analyses using 
methods other than inverse variance, we assessed differences between subgroups by 
inspection of the subgroups’ CIs; non-overlapping CIs indicate a statistically signiﬁcant 
difference in treatment effect between the subgroups. 
2.3.11 Sensitivity analysis 
We planned to explore the impact of the level of bias through undertaking sensitivity 
analyses (low versus high or unclear risk trials) but the retrieved trials were classiﬁed as 
high risk. Finally, we also planned to explore the change of the point estimate through the 
inclusion and exclusion of trials with patients that had been previously treated, but the 
number of retrieved trials recruiting naive population limited this approach: just one trial 
included a naive population for the comparison between imiquimod versus any other 
patient-applied treatment (Komericki 2011), and one trial for the comparison of imiquimod 
versus any other provideradministered treatment (Stefanaki 2008). 
2.3.12 Grading the quality of evidence 
The GRADE approach speciﬁes four levels of quality (high, moderate, low and very low) 
starting from high for RCTs (Higgins 2011). Where the included RCTs had quality ﬂaws, we 
downgraded the quality of evidence by one level depending on the presence of the following 
factors (Higgins 2011): 
1. Study limitations (risk of bias). 
2. Inconsistency of results. 
3. Indirectness of evidence. 
4. Imprecision. 
5. Publication bias. 
2.3.13 Diferences between protocol and review 
During the protocol stage, we stated our intention to explore the duration of therapy (< eight 
weeks; ≥ eight weeks) and the lesion site (perineal or perianal skin) as potential sources of 
heterogeneity. However, we discovered two limitations of this approach during data 
extraction. Firstly, all the included trials provided therapy for longer than eight weeks 
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(making impossible to perform the subgroup analysis proposed). Secondly, the retrieved 
studies usually reported by two or more different sites of lesion. Therefore, we re-deﬁned 
the ﬁrst subgroup analyses as 12 weeks or less and more than 12 weeks for duration of 
therapy and we synthesized the other sites reported through a third category named “other 
lesion site” for the second subgroup. We deﬁned all this adjustments before performing 
data analysis. 
We decided to restrict our subgroup analyses to the principal comparison imiquimod versus 
placebo because it provided enough clinical trials to perform the analysis. Finally, in order 
to overcome a unit-of-analysis error, for trials that could contribute multiple, correlated 
comparisons, we used two approaches: we combined all relevant experimental intervention 
groups of the studies into a single group and also combined all relevant control intervention 
groups into a single control group, in order to create a single pair-wise comparison (Higgins 
2011) when the objective was compare the experimental branch with any other control 
group (e.g. imiquimod versus placebo). However, when the objective was to detect 
differences into the experimental groups (e.g. between different imiquimod concentrations), 
we split the sample of the control group in order to realize the respective comparison 
(Higgins 2011).  
We planned to explore the impact of the level of bias through undertaking sensitivity 
analyses (low versus high or unclear risk trials) but all the included trials were classiﬁed as 
high risk, making this impossible. The deﬁnition of partial regression after treatment (at least 
a 50% of clearance of the lesions) was added after the protocol.  
Finally, we excluded three studies due to a serious risk of fraud (Syed 1998; Syed 2000; 
Syed 2002). We considered this as an exclusion criterion, rather than a source of bias. 
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3. Results4 
3.1 Description of studies 
3.1.1 Results of the search 
We retrieved a total of 1150 references and screened 905 after we removed duplicated 
references. Of these, we initially screened 77 references as RCTs. Ten published trials met 
our inclusion criteria (Arican 2004; Baker 2011; Beutner 1998; Beutner 1998a; Edwards 
1998; Komericki 2011; Padhiar 2006; Schofer 2006; Stefanaki 2008; Tyring 1998; see 
Figure 3.1). We excluded 61 studies (see Characteristics of excluded studies) and three 
trials are awaiting classiﬁcation (Characteristics of studies awaiting classiﬁcation). Three of 
the excluded studies contain fraudulent information (Syed 1998; Syed 2000; Syed 2002); 
the Manager Editor of the STI CRG notiﬁed the review authors about this ﬁnding. 
                                               
 
4 This document has been published elsewhere as form of the review entitled Imiquimod for 
anogenital warts in non-immunocompromised adults, published in The Cochrane Library 2014, Issue 
11; available on: http://www.thecochranelibrary.com 
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Figure 3-1: Study flow diagram. 
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3.1.2 Included studies 
The 10 included trials had a total of 1734 participants, with a simple size ranging from 22 
to 534 participants. These trials were fromAustria (Komericki 2011), Germany (Schofer 
2006), Greece (Stefanaki 2008), India (Padhiar 2006), Turkey (Arican 2004) and USA 
(Baker 2011; Beutner 1998; Beutner 1998a; Edwards 1998, Tyring 1998). Five were 
multicentric trials (Baker 2011; Beutner 1998; Beutner 1998a; Edwards 1998; Schofer 
2006) and three trials recruited the participants into a sexually transmitted clinic (Komericki 
2011; Padhiar 2006; Stefanaki 2008). Three trials implemented a valid method for sample 
size calculation in advance (Beutner 1998a; Komericki 2011; Schofer 2006). All included 
trials were published in English. 
Population 
The included trials recruited men and women aged over 18 years old. However, one trial 
included participants aged between 15 and 81 years (Baker 2011); another trial that was 
designed to include people aged over 12 years old ended up recruiting participants aged 
between 26 and 35 years old (Padhiar 2006); and two trials included only men (Stefanaki 
2008) or women (Baker 2011). The most common diagnostic pathway used to conﬁrmed 
the presence of the condition was the clinician’s judgment, but three trials implemented a 
combination of clinical and histopathological diagnostic (Beutner 1998; Beutner 1998a; 
Tyring 1998). 
The selected trials recruited participants with AGW regardless of their location, shape, size, 
number or compromised area, except for ﬁve trials that implemented some type of exclusion 
criteria related with the clinical characteristics of the disease. One trial limited the 
compromised area to 20 cm2 (Schofer 2006) and three trials used the number of AGWas a 
inclusion criteria: between two and 30 (Baker 2011) and between two and 50 lesions 
(Beutner 1998; Edwards 1998; Padhiar 2006). 
Finally, seven trials included people with a previous history of treatment (Arican 2004; Baker 
2011; Beutner 1998; Beutner 1998a; Edwards 1998; Schofer 2006; Tyring 1998), two trials 
included naive population (Komericki 2011; Stefanaki 2008) and one trial did not mentioned 
this characteristic (Padhiar 2006). 
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Interventions 
The most frequently used concentration of imiquimod was 5% (Arican 2004; Beutner 1998a; 
Komericki 2011; Padhiar 2006; Schofer 2006; Stefanaki 2008; Tyring 1998). However, 
three trials also assessed other dosages: 2.5%or 3.75%in Baker 2011 and 1% in Beutner 
1998 and Edwards 1998. 
Eight trials reported an administration frequency of three times per week (Arican 2004; 
Beutner 1998a; Edwards 1998; Komericki 2011; Padhiar 2006; Schofer 2006; Stefanaki 
2008; Tyring 1998) and two trials administrated it daily (Baker 2011; Beutner 1998).  
Six trials had a maximum therapy duration of 16 weeks, in two trials the length of the therapy 
was twelve weeks (Arican 2004; Stefanaki 2008) and in two trials it was eight weeks (Baker 
2011; Beutner 1998a). All the included trials established, as an alternative to the length of 
therapy, the time until complete disappearance of the lesions. 
Comparisons 
Six trials used a vehicle creamas placebo (Arican 2004; Baker 2011; Beutner 1998; Beutner 
1998a; Edwards 1998; Tyring 1998). Two trials compared the effectiveness of imiquimod 
cream with a patient-applied treatment: podophyllotoxin (Komericki 2011) or podophyllin 
20% (Padhiar 2006). In Komericki 2011, participants received treatment twice a day on 
three consecutive days per week until the warts completely cleared or up to four weeks. In 
Padhiar 2006, podophyllin was used once a week for maximum of six weeks (Padhiar 
2006). Moreover, two trials compared the imiquimod cream with another provider-
administered treatment: ablative methods (electrocautery, liquid nitrogen, laser therapy or 
surgical removal) over a period of four weeks until all visible AGW were removed (Schofer 
2006) and cryotherapy once every three weeks for three consecutive sessions (Stefanaki 
2008). 
Outcomes 
Although the included trials reported at least one prespeciﬁed primary outcome of this 
review, there were some differences in reporting and deﬁnition of the outcomes between 
trials. All trial authors reported complete regression of the lesions as the total clearance of 
the warts. Four trials deﬁned partial regression as at least a 50% of clearance of the lesions 
(Arican 2004; Beutner 1998; Beutner 1998a; Edwards 1998) and two trials deﬁned it as at 
28 Imiquimod for anogenital warts in non-immunocompromised 
adults (Review) 
 
least 75% of clearance of the lesion (Baker 2011; Tyring 1998). Four trials did not evaluate 
this outcome (Padhiar 2006; Komericki 2011; Schofer 2006; Stefanaki 2008). The included 
trials also reported time to complete regression, recurrence during follow-up, the 
appearance of new warts during treatment, and the local or systemic reactions during 
therapy. We did not obtain any data on the primary outcome dyspareunia after treatment 
or on the secondary outcomes: relief of symptoms during treatment, excessive scarring, 
time to resumption of intercourse, pain during therapy, pigmentary changes at application 
site, requirement of any additional treatment, patient’s satisfaction with treatment and cost 
effectiveness of intervention. 
Length of follow-up 
The participants were monitored for two (Beutner 1998a), three (Beutner 1998), four 
(Komericki 2011; Tyring 1998), six (Arican 2004; Padhiar 2006; Schofer 2006) or 12 months 
(Baker 2011; Edwards 1998; Stefanaki 2008). 
3.2 Risk of bias in included studies 
We have summarized the risk of bias assessment in Figure 3.2 and Figure 3.3. Also, we 
provided additional details of the included trials in the Characteristics of included studies 
tables. 
Figure 3-2: Risk of bias graph: review authors’ judgements about each risk of bias item 
presented as percentages across all included trials. 
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Figure 3-3: Risk of bias summary: review authors’ judgements about each risk of bias 
item for each included trial. 
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3.2.1 Allocation 
Random sequence generation (checking for possible selection 
bias) 
Three trials (Baker 2011; Komericki 2011; Schofer 2006) adequately reported the random 
sequence generation method by using a computer-generated randomization list, making 
selection bias at entry unlikely. In Tyring 1998, random sequence generation was broken 
because two lost participants were directly replaced, making the selection bias likely at 
entry. The remaining included trials (Arican 2004; Beutner 1998; Beutner 1998a; Edwards 
1998; Padhiar 2006; Stefanaki 2008) did not report the randomsequence generation 
methods, making the risk of selection bias at entry unclear. 
Allocation concealment (checking for possible selection bias) 
One trial (Baker 2011) implemented sequentially numbered drugs containers as a 
concealment allocation method, making selection bias at entry unlikely. Komericki 2011 
was an open label trial and used a block randomization process (block contained two 
allocation for each group). As the intervention allocation could have been foreseen, 
selection bias at entry was likely. Also, Tyring 1998 probably did not implement any 
allocation concealment method because two lost participants were directly replaced, one 
to each group, making the selection bias likely. The seven remaining included trials (Arican 
2004; Beutner 1998; Beutner 1998a; Edwards 1998; Padhiar 2006; Schofer 2006; 
Stefanaki 2008) did not report the method used to conceal allocation to interventions prior 
to assignment, making the risk of selection bias at entry unclear. 
3.2.2 Blinding 
One trial (Baker 2011) used placebo with identical appearance for the control group to blind 
trial participants and personnel, making performance bias unlikely. The trial authors 
assessed two outcomes, complete and partial regression after treatment and recurrence 
during follow-up, objectively in contrast with outcomes such as pain and any local reactions 
during therapy, which were subjectively evaluated. However, we judge that the blinding of 
the outcome assessors fromknowledge of which intervention each participant received 
prevented detection bias. 
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Three trials (Komericki 2011; Schofer 2006; Stefanaki 2008) were unblinded to personnel 
and trial participants and was at high risk of performance bias. We appraised the outcomes 
complete regression, recurrence during follow-up and appearance of new warts during 
treatment as at low risk of detection bias. This is because they were objectively assessed 
and lack of blinding of the outcome assessor was unlikely to affect the results. On the other 
hand, the trial authors assessed the outcomes pain, local adverse reaction and systemic 
adverse reaction during therapy, subjectively and the lack of blinding of the outcome 
assessors from knowledge of which intervention a participant received made detection bias 
possible. 
Six trials (Arican 2004; Beutner 1998; Beutner 1998a; Edwards 1998; Padhiar 2006; Tyring 
1998) did not specify how the participants and the personnel were blinded from knowledge 
of which intervention a participant received, making unclear the risk of performance bias. 
Appraising for detection bias, the outcomes complete regression after treatment, partial 
regression after treatment, recurrence during follow-up and appearance of new warts during 
treatment, were objectively assessed. Lack of blinding of the outcome assessor was 
unlikely to affect the results. For the outcomes any local reactions during therapy, any 
systemic reactions during therapy and pain during therapy, the risk of detection bias was 
unclear because the reports did not provide enough information to judge the risk of bias. 
3.2.3 Incomplete outcome data 
Three trials (Arican 2004; Komericki 2011; Tyring 1998) appropriately stated the attrition 
and exclusions at each stage; the reasons were balanced across groups. In addition, the 
level of missing data was not over 20%and the attrition or exclusion probably was not 
related with the outcomes, making attrition bias unlikely. 
Edwards 1998 had a discontinuation rate and follow-up loss greater than 20%. The trial 
authors conducted intention-to-treat analysis for efﬁcacy and per protocol analysis for safety 
outcomes. We appraised it as at high risk of attrition bias. 
Stefanaki 2008 performed per protocol analysis, there was over 20% loss to follow-up and 
the trial authors did not state reasons for it. We judged it at high risk of attrition bias. 
Two trials (Baker 2011; Beutner 1998) had missing data greater that 20%, the reasons were 
stated and they were balanced across trial groups; the authors conducted the analyses only 
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for those subjects completely treated (per protocol analysis). We assessed these trials as 
at high risk of bias. 
Beutner 1998a did intention-to-treat analysis for one outcome only (complete clearance) 
and performed per protocol analysis for the remaining six outcomes; withdrawals were 
fewer than 20%, they were described and balanced between the groups. We appraised this 
trial as at high risk of attrition bias. 
One trial (Schofer 2006) undertook per-protocol analysis; there was under 20% withdrawal 
but the reasons were not balanced across groups. We considered it as at high risk of 
attrition bias. Finally, one trial (Padhiar 2006) did not have enough information to permit 
judgment of “yes” or “no” (rated as “unclear” risk of bias). 
3.2.4 Selective reporting 
In one trial (Baker 2011) the authors selected time to complete regression as one of the 
primary outcomes, but this outcome was not mentioned in the results section. Some 
subgroups which had not been pre-speciﬁed were analyzed, as the rate for regression of 
lesions and the risk of recurrence by age, race, gender, wart area and number of warts. 
Finally, despite designing the trial to assess the effectiveness and safety of the intervention 
among male and female (protocols number NCT00674739 and NCT00735462), they 
reported only those results of the included females. Thus, we judged this trial as at high risk 
of selective reporting bias. 
Another trial (Stefanaki 2008) did not mention the outcome time to regression and 
recurrence in the methods section, but these outcomes were reported in the outcome 
section. The trial authors conducted some sub-group analyses and reported them in the 
results section, but these were not pre-deﬁned or mentioned in the methods section. We 
judged this trial at high risk of selective reporting bias. 
Tyring 1998 stated any systemic reactions as an outcome in the methods section, but the 
trial authors did not report this outcome in the results section. 
For seven trials (Arican 2004; Beutner 1998; Beutner 1998a; Edwards 1998; Komericki 
2011; Padhiar 2006; Schofer 2006) the trial protocol is not available and it is unclear if the 
published reports included all the expected outcomes, including those that were 
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prespeciﬁed. The report had insufﬁcient information to permit judgment of “yes” or “No” 
(rated as “unclear” risk of bias). 
3.2.5 Other potential sources of bias 
Six trials had a potential source of bias related to being funded by pharmaceutical 
companies (Baker 2011; Beutner 1998; Beutner 1998a; Edwards 1998; Schofer 2006; 
Tyring 1998). The remaining four trials appeared to be free fromother sources of bias 
(Arican 2004; Komericki 2011; Padhiar 2006; Stefanaki 2008). 
3.3 Effects of interventions 
See: Summary of ﬁndings for the main comparison Imiquimod compared to placebo for 
anogenital warts in non-immunocompromised adults; Summary of ﬁndings 2 Imiquimod 
compared to any other patient-applied treatment for anogenital warts in non-
immunocompromised adults; Summary of ﬁndings 3 Imiquimod compared to any other 
provider-administered treatment for anogenital warts in nonimmunocompromised adults. 
3.3.1 Imiquimod versus placebo 
Six trials including 1294 patients compared imiquimod to placebo. However, they did not all 
contribute data to each outcome. 
Complete regression after treatment 
The results correspond to the meta-analysis of six trials (Arican 2004; Baker 2011; Beutner 
1998; Beutner 1998a; Edwards 1998; Tyring 1998). Imiquimod was associated with a 
signiﬁcantly improved complete lesion regression when compared to placebo (RR 4.03, 
95% CI 2.03 to 7.99; six trials, 1294 patients, I2 statistic = 60%; Analysis 1.1; Figure 3.4). 
The quality of evidence was very low due to the limitations of risk of bias and inconsistency. 
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Figure 3-4: Forest plot of comparison: 3.3.1 Imiquimod versus placebo, Analysis 1.1: 
Complete regression after treatment.  
 
Partial regression after treatment 
The results correspond to the meta-analysis of six trials (Arican 2004; Baker 2011; Beutner 
1998; Beutner 1998a; Edwards 1998; Tyring 1998). Imiquimod was associated with a 
signiﬁcantly improved partial lesion regression when compared to placebo (RR 2.56, 95% 
CI 2.05 to 3.20; six trials, 1082 patients, I2 statistic = 0%; Analysis 1.2; Figure 3.5). The 
quality of evidence was very low due to the limitations of risk of bias and inconsistency. 
Figure 3-5: Forest plot of comparison: 3.3.1 Imiquimod versus placebo, Analysis 1.2: 
Partial regression after treatment. 
 
Recurrence during follow-up (from 0 to six months) 
The results correspond to the meta-analysis of four trials (Baker 2011; Beutner 1998; 
Beutner 1998a; Edwards 1998). There was no evidence of a signiﬁcant difference between 
placebo and imiquimod in the rate of recurrence of the lesions until six months after 
treatment (RR 2.76, 95% CI 0.70 to 10.91; three trials, 270 participants, I2 statistic = 0%; 
Analysis 1.3; Figure 3.6). The quality of evidence was very low due to the limitations of risk 
of bias and imprecision. 
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Figure 3-6: Forest plot of comparison: 3.3.1 Imiquimod versus placebo, Analysis 1.3: 
Recurrence during follow-up from 0 to six months. 
 
Appearance of new warts during treatment 
Three trials informed this outcome (Beutner 1998; Beutner 1998a; Edwards 1998). There 
was no evidence of statistically signiﬁcance difference between imiquimod and placebo (RR 
0.76, 95% CI 0.58 to 1.00; three trials, 671 patients, I2 statistic = 49%; Analysis 1.4 ; Figure 
3.7). The quality of evidence was very low due to the limitations of risk of bias, inconsistency 
and imprecision. 
Figure 3-7: Forest plot of comparison: 3.3.1 Imiquimod versus placebo, Analysis 1.4: 
Appearance of new warts during treatment. 
 
Pain during therapy 
The meta-analysis of two trials (Baker 2011; Beutner 1998), showed a signiﬁcant higher 
rate of pain with imiquimod compared to placebo (RR 11.84, 95% CI 3.36 to 41.63; two 
trials, 804 participants, I2 statistic = 0%; Analysis 1.5; Figure 3.8). The quality of evidence 
was low due to the limitations of risk of bias. 
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Figure 3-8: Forest plot of comparison: 3.3.1 Imiquimod versus placebo, Analysis 1.5: 
Pain during therapy. 
 
Any local reaction during therapy  
The results correspond to the meta-analysis of ﬁve trials (Arican 2004; Baker 2011; Beutner 
1998; Beutner 1998a; Edwards 1998). There was a signiﬁcant higher rate of any local 
reaction during the therapy with imiquimod compared to placebo (RR 1.73, 95% CI 1.18 to 
2.53; ﬁve trials, 1225 participants, I2 statistic = 73%; Analysis 1.6; Figure 3.9). The quality 
of evidence was very low due to the limitations of risk of bias, inconsistency and imprecision. 
Figure 3-9: Forest plot of comparison: 3.3.1 Imiquimod versus placebo, Analysis 1.6: 
Any local reactions during therapy. 
 
Any systemic reaction during therapy 
There was no evidence of signiﬁcant difference between placebo and imiquimod in the rate 
of systemic reactions during the therapy, in the meta-analysis of two trials ( Arican 2004; 
Beutner 1998) (RR 0.91, 95% CI 0.63 to 1.32; two trials, 313 patients, I2 statistic = 0%; 
Analysis 1.7; Figure 3.10). The quality of evidence was low due to the limitations of risk of 
bias and imprecision. 
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Figure 3-10: Forest plot of comparison: 3.3.1 Imiquimod versus placebo, Analysis 1.7: 
Any systemic reactions during therapy. 
 
3.3.2 Imiquimod versus any other patient-applied treatment 
Two trials including 105 patients compared imiquimod to any other patient-applied 
treatment (podophyllotoxin and podophyllin) but they did not all contribute data to each 
outcome. 
Complete regression after treatment 
The results correspond to meta-analysis of two trials (Komericki 2011; Padhiar 2006). There 
was no evidence of signiﬁcant difference between imiquimod and any other patient-applied 
treatment in the total clearance of the AGW(RR 1.09, 95%CI 0.80 to 1.48; two trials, 105 
patients, I2 statistic = 0%; Analysis 2.1; Figure 3.11). The quality of evidence was very low 
due to the limitations of risk of bias and imprecision. 
Figure 3-11: Forest plot of comparison: 3.3.2 Imiquimod versus placebo, Analysis 2.1: 
Complete regression after treatment. 
 
Partial regression after treatment 
Only Padhiar 2006 reported on this outcome. There was no evidence of signiﬁcant 
difference between imiquimod and any other patient-applied treatment (podophyllotoxin) in 
the partial regression of the lesions (RR 0.77, 95% CI 0.40 to 1.47; one trial, 60 patients; 
Analysis 2.2; Figure 3.12). The quality of evidence was low due to the limitations of risk of 
bias and imprecision. 
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Figure 3-12: Forest plot of comparison: 3.3.2 Imiquimod versus placebo, Analysis 2.2: 
Partial regression after treatment. 
 
Recurrence during follow-up (from 0 to six months) 
The results correspond to one trial (Padhiar 2006). There was no evidence of signiﬁcant 
difference between imiquimod and any other patient-applied treatment (podophyllotoxin) in 
the rate of recurrence of the lesions until six months after treatment (RR0.49, 95%CI 0.21 
to 1.11; one trial, 30 participants; Analysis 2.3; Figure 3.13). The quality of evidence was 
low due to the limitations of risk of bias and imprecision. 
Figure 3-13: Forest plot of comparison: 3.3.2 Imiquimod versus placebo, Analysis 2.3: 
Recurrence during follow-up from 0 to six months. 
 
Any local reaction during therapy  
The results correspond to meta-analysis of two trials (Komericki 2011; Padhiar 2006). There 
was no evidence of signiﬁcant difference in the presence of any local reaction during the 
therapy with imiquimod compared to any other patient-applied treatment (podophyllin 20% 
and podophyllotoxin) (RR 1.24, 95% CI 1.00 to 1.54; two trials, 105 participants, I2 statistic 
= 0%; Analysis 2.4; Figure 3.14). The quality of evidence was very low due to the limitations 
of risk of bias and imprecision. Any systemic reaction during therapy 
Figure 3-14: Forest plot of comparison: 3.3.2 Imiquimod versus placebo, Analysis 2.4: 
Any local reactions during therapy. 
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Any systemic reaction during therapy 
One trial reported on this outcome (Padhiar 2006). There were signiﬁcantly fewer systemic 
reactions during the therapy with imiquimod compared with any other patient-applied 
treatment (RR 0.30, 95% CI 0.09 to 0.98; one trial, 60 patients; Analysis 2.5; Figure 3.15). 
The quality of evidence was low due to the limitations of risk of bias and imprecision. 
Figure 3-15: Forest plot of comparison: 3.3.2 Imiquimod versus placebo, Analysis 2.5: 
Any systemic reactions during therapy. 
 
3.3.3 Imiquimod versus any other provider-administered 
treatment 
Two trials (335 patients) compared imiquimod to any other provider-administered treatment 
(ablative methods and cryotherapy) but they did not all contribute data to each outcome. 
Complete regression after treatment 
The results correspond to the meta-analysis of two trials (Schofer 2006; Stefanaki 2008). 
There was no evidence of signiﬁcant difference between imiquimod and provider-
administered treatment in the total clearance of the AGW(RR 0.84, 95%CI 0.56 to 1.28; two 
trials, 335 patients, I2 statistic = 84%; Analysis 3.1; Figure 3.16). The quality of evidence 
was very low due to the limitations of risk of bias, imprecision and inconsistency. 
Figure 3-16: Forest plot of comparison: 3.3.3 Imiquimod versus placebo, Analysis 3.1: 
Complete regression after treatment. 
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Recurrence during follow-up (from 0 to six months) 
The results correspond to one trial (Schofer 2006). There was a signiﬁcant reduction in the 
rate of recurrence of the lesions until six months after treatment with imiquimod compared 
with provideradministered treatment (RR 0.24, 95% CI 0.10 to 0.56; one trial, 192 
participants; Analysis 3.2; Figure 3.17). The quality of evidence was very low due to 
limitations of risk of bias and imprecision. 
Figure 3-17: Forest plot of comparison: 3.3.3 Imiquimod versus placebo, Analysis 3.2: 
Recurrence during follow-up from 0 to six months. 
 
Recurrence during follow-up (from six to 12 months) 
The results correspond to one trial (Stefanaki 2008). There was no evidence of signiﬁcant 
difference in the rate of recurrence of the lesions between six and 12 months after treatment 
with imiquimod compared with provider-administered treatment (RR 0.71, 95% CI 0.40 to 
1.25; one trial, 53 participants; Analysis 3.3; Figure 3.18). The quality of evidence was very 
low due to the limitations of risk of bias and imprecision. 
Figure 3-18: Forest plot of comparison: 3.3.3 Imiquimod versus placebo, Analysis 3.3: 
Recurrence during follow-up from six to 12 months. 
 
Pain during therapy 
One trial reported this outcome (Stefanaki 2008). There was less pain during the therapy 
with imiquimod than with provider-administered treatment (cryotherapy in this trial) (RR 
0.30, 95%CI 0.17 to 0.54; one trial, 80 participants; Analysis 3.4; Figure 3.19). The quality 
of evidence was very low due to the limitations of risk of bias and imprecision. 
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Figure 3-19: Forest plot of comparison: 3.3.3 Imiquimod versus placebo, Analysis 3.4: 
Pain during therapy. 
 
Any local reaction during therapy  
The results correspond to one trial (Stefanaki 2008). There was a signiﬁcant reduction in 
the presence of any local adverse reaction during the therapy with imiquimod compared to 
the provideradministered treatment (cryotherapy in this trial) (RR 0.55, 95% CI 0.40 to 0.74; 
one trial, 80 participants; Analysis 3.5; Figure 3.20). The quality of evidence was very low 
due to the limitations of risk of bias and imprecision. 
Figure 3-20: Forest plot of comparison: 3.3.3 Imiquimod versus placebo, Analysis 3.5: 
Any local reactions during therapy. 
 
3.3.4 Subgroup analysis and investigation of heterogenity 
We performed subgroup analyses to explore the substantial heterogeneity we found in the 
analyses “Complete regression” for the comparison imiquimod versus placebo. For this 
analysis (overall effect I2 statistic = 60%) we explored whether differences in concentration 
of imiquimod (less than 5%; 5% or more), duration of therapy (12 weeks or less, or more 
than 12 weeks), times per week (once daily; any other frequency per week), lesion site 
(perineal, perianal or any other location) and sex of the patient reduced the heterogeneity 
in the overall effect size. 
Neither of the tests for subgroup effect were signiﬁcantly different when we explored 
heterogeneity source by: concentration of imiquimod (P = 0.09; Analysis 4.1), duration of 
therapy (P = 0.67; Analysis 5.1), times per week (P = 0.92; Analysis 6.1), lesion site (P = 
0.37; Analysis 7.1) and sex of the patient (P = 0.11; Analysis 8.1). Subgroup analysis did 
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not appear to explain the variability in the overall summary effect measures for outcome 
complete regression, so these ﬁndings should be interpreted with caution. 
In the analyses “Partial regression” for the comparison imiquimod versus placebo, neither 
of the tests for subgroup effect showed evidence of statistically signiﬁcant differences, 
analyzing by: concentration of imiquimod (P = 0.08; Analysis 9.1), duration of therapy (P = 
0.20; Analysis 10.1), times per week (P = 0.38; Analysis 11.1), lesion site (P = 0.83; Analysis 
12.1) and sex of the patient (P = 0.66; Analysis 13.1). The effect of the intervention for this 
outcome did not change according to these population or intervention characteristics. 
However, this ﬁnding should be interpreted with caution based on the very low quality of 
the evidence. 
We did not perform the subgroup analysis “severity of the disease” because none of the 
included trials provided information on this basal condition. The subgroup analyses were 
restricted to the comparison of imiquimod versus placebo and the primary outcome: 
complete and partial regression at the end of the treatment. For the primary outcome 
dyspareunia after treatment, none of the included trials provided information. 
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4. Discussion5 
4.1 Summary of main results 
Ten RCTs (1734 participants) met the inclusion criteria. We judged the risk of bias for the 
included trials to be high. Six trials (1294 participants) compared the use of imiquimod 
versus placebo. There was very low quality evidence that imiquimod was superior to 
placebo in achieving complete (RR 4.03, 95%CI 2.03 to 7.99) and partial regression (RR 
2.56, 95% CI 2.05 to 3.20). When compared with placebo the effects of imiquimod on 
recurrence (RR 2.76, 95% CI 0.70 to 10.91), appearance of new warts (RR 0.76, 95% CI 
0.58 to 1.00) and frequency of systemic adverse reactions (RR 0.91, 95% CI 0.63 to 1.32) 
were imprecise. We downgraded the quality of evidence to low or very low. There was low 
quality evidence that imiquimod led to more local adverse reactions (RR 1.73, 95% CI 1.18 
to 2.53) and pain (RR 11.84, 95% CI 3.36 to 41.63). 
Two trials (105 participants) compared the use of imiquimod versus any other patient-
applied treatment (podophyllotoxin or podophyllin). The estimated effects of imiquimod on 
complete regression (RR 1.09, 95%CI 0.80 to 1.48), partial regression (RR 0.77, 95%CI 
0.40 to 1.47), recurrence (RR 0.49, 95%CI 0.21 to 1.11) or the presence of local adverse 
reactions (RR 1.24, 95% CI 1.00 to 1.54) were imprecise (very low quality evidence). There 
was low quality evidence that systemic adverse reactions were less frequent with imiquimod 
(RR 0.30, 95% CI 0.09 to 0.98).  
                                               
 
5 This document has been published elsewhere as form of the review entitled Imiquimod for 
anogenital warts in non-immunocompromised adults, published in The Cochrane Library 2014, Issue 
11; available on: http://www.thecochranelibrary.com 
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Finally, two trials (335 participants) compared imiquimod with any other provider-
administered treatment (ablative methods and cryotherapy). There was very low quality of 
evidence that imiquimod did not had a lower frequency of complete regression (RR 0.84, 
95% CI 0.56 to 1.28). There was very low quality evidence that imiquimod led to a lower 
rate of recurrence during sixmonth follow-up (RR 0.24, 95% CI 0.10 to 0.56) but this did not 
translate in to a lower recurrence from six to 12 months (RR 0.71, 95% CI 0.40 to 1.25; very 
low quality evidence). There was very low quality evidence that imiquimod was associated 
with less pain (RR 0.30, 95% CI 0.17 to 0.54) and fewer local reactions (RR 0.55, 95% CI 
0.40 to 0.74). 
4.2 Overall completeness and applicability of evidence 
Although we conducted comprehensive searches to retrieve all published and unpublished 
RCTs, this systematic review included trials at high risk of bias and consequently with low 
conﬁdence on the estimate of effect (see Summary of ﬁndings for the main comparison; 
Summary of ﬁndings 2; Summary of ﬁndings 3). Additionally, the data are incomplete, and 
some of the important clinical outcomes were not reported. For example, none of the 
included trials assessed the frequency of dyspareunia after treatment, the time to complete 
regression, the relief of symptoms during treatment, the excessive scarring or the 
pigmentary changes at application site, the requirement of any additional therapy, the 
patient’s satisfaction with treatment or the cost effectiveness of the intervention.  
The applicability of the evidence into the target population (men and non-pregnant women 
with immunocompetence and aged over 16 years) is broad because the retrieved trials 
were conducted in different clinical settings. The interventions analyzed in the review and 
the patient-applied treatments (included imiquimod) are available in various clinical 
settings; contrasting with the provideradministered treatments (e.g. cryotherapy or surgical 
removal) which require substantial clinical training, additional equipment, local or general 
anesthesia and longer ofﬁce visits. When imiquimod was compared with the other patient-
applied treatments (e.g. podoﬁlox), imiquimod had the advantage of being an intervention 
with a minor frequency of systemic side-effects with similar effectiveness. 
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4.3 Quality of the evidence 
We considered the 10 included trials to be at high risk of bias and the conﬁdence in the 
estimated effect was very low (see Summary of ﬁndings for the main comparison; Summary 
of ﬁndings 2; Summary of ﬁndings 3). There is little conﬁdence in the effect estimates; the 
true effect is likely to be substantially different. The conﬁdence is very low due to trial 
limitations (lack of blinding, failure to adhere to the intention-to-treat principle, selective 
reporting and other risk of bias), inconsistency (unexplained variability in some results) and 
some imprecise results (few women and outcome events with wide CIs). We could not 
evaluate publication bias, because there were too few included trials into each comparison. 
4.4 Potential biases in the review process 
We had concerns about publication bias (see Summary of ﬁndings for the main comparison; 
Summary of ﬁndings 2; Summary of ﬁndings 3). Publication bias is a possibility because 
the included trials were mostly funded by industry and due to the limited number of trials for 
each comparison. It is known that the risk of publication bias is probably higher for reviews 
that are based on sponsored trials. Another important limitation of this systematic review is 
the measurement bias present in the available RCTs, especially when the trial authors 
assessed outcomes subjectively. There was substantial heterogeneity for some outcomes 
and our investigation of heterogeneity sources (which was based on a small amount of trials 
for each comparison) could have limited value. Finally, although the trial authors deﬁned by 
consensus the subgroup analysis of duration of therapy and the lesion site before they 
carried out the data analysis, these results should be interpreted with caution.
  
  
 
  
5. Authors’ conclussions6 
5.1 Implications for practice 
Due to risk of bias, imprecision and inconsistency for many of the outcomes we have 
assessed in this Cochrane Review, the beneﬁts and harms of imiquimod compared with 
placebo should be regarded with caution. The evidence for many of the outcomes that show 
imiquimod and patient-applied treatment (podophyllotoxin or podophyllin) confer similar 
beneﬁts but fewer systematic reactions with the Imiquimod, is of low or very low quality. 
The quality of evidence for the outcomes assessing imiquimod and other provider-
administered treatment were of very low quality. 
5.2 Implications for research 
There is a need for high quality RCTs on treatments for the patients with AGW, particularly 
comparing imiquimod versus any other patient or provider-administered treatment. Further 
research should focus on avoiding risk of bias as lack of blinding, failure to adhere to the 
intention-to-treat principle and selective reporting. Future studies should report important 
clinical outcomes as: frequency of dyspareunia after treatment, time to complete 
regression, excessive scarring or the pigmentary changes at application site, the 
requirement of any additional therapy, the patient’s satisfaction with treatment or the cost 
effectiveness of intervention inter alia. 
 
 
 
 
                                               
 
6 This document has been published elsewhere as form of the review entitled Imiquimod for 
anogenital warts in non-immunocompromised adults, published in The Cochrane Library 2014, Issue 
11; available on: http://www.thecochranelibrary.com 
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A. Appendix 1: Summary of findings7  
Summary of findings for the main comparison 
 
 
                                               
 
7 This document has been published elsewhere as form of the review entitled Imiquimod for 
anogenital warts in non-immunocompromised adults, published in The Cochrane Library 2014, Issue 
11; available on: http://www.thecochranelibrary.com 
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Additional summary of findings   
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B. Appendix 2: Characteristics of 
studies8 
Tabla 1: Characteistics of included studies. 
 
Arican 2004 
Methods  
 
Setting: Turkey, outpatient clinic 
Trial design: RCT, parallel two arms 
Funding sources: Not reported 
Ethical issues: “Patients that participated in the study provided their consent 
after they were informed about the treatment options and the course of the 
study” 
Participants Inclusion criteria: 
• Volunteer patients 
• Not received any therapies within the previous three months 
• 18 years of age or more 
Exclusion criteria: 
• Patients with a pathological condition 
• Immunosuppressive or serious systemic disorders 
• Alcoholics and substance dependent 
• Frequently recurrent genital herpes 
• Patients who had undergone a local or systemic therapy within the last three 
months 
Population 
Number of participants: Total 45 (34 allocated to imiquimod and 11 to placebo). 
Mean age (SD): IQ5%: 30.3 (6.1). Placebo: 32.3 (6.8). 
Site of lesions by sex: Female: genital: 5, perianal: 5, mixed:1. Placebo: genital: 1, 
perianal: 1 and mixed: 0; Male: genital: 14, perianal: 7, mixed:1. Placebo: genital: 6, 
perianal: 1, mixed: 1 
Number of participants who received previous treatment: Unclear. 
Interventions Total number of intervention groups: 2 groups. 
Intervention: Imiquimod 5% cream three times a week, every other day for 12 
weeks 
Control: Vaseline cream three times a week, every other day for 12 weeks 
Outcomes During the ﬁrst examination, regional lesions were determined and mapped, and the 
localizations and periods of the lesions were recorded. During the duration of the 
therapy, the lesions were re-assessed re-mapped and the side effects of the drug 
were investigated. 
                                               
 
8 This document has been published elsewhere as form of the review entitled Imiquimod for 
anogenital warts in non-immunocompromised adults, published in The Cochrane Library 2014, Issue 
11; available on: http://www.thecochranelibrary.com 
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When warts were removed, the treatment was interrupted, and the patients were 
followed-up. 
At the end of the therapy patients were assessed for recurrences for a period 
of six months in monthly visits 
• Complete regression after treatment (total clearance of the warts) 
• Partial regression after treatment (reduction at least 50% of wart area) 
• Any local reactions during therapy (erosion, erythema, erythema and erosion, 
erythema and excoriation, burning sensation or itching) 
• Any systemic reactions during therapy (inﬂuenza-like symptoms) 
Notes Additional information requested from trial authors by e-mail (no answer) 
   
Risk of bias  
Bias 
 
Authors’ judgement 
 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk “This study was planned as 
randomised, double-blind and placebo-
controlled.” Comment: No information 
available to make a judgement. 
Allocation concealment 
(selection bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Blinding of participants and 
personnel 
(performance bias) 
All outcomes 
Unclear risk “This study was planned as 
randomised, double-blind and placebo-
controlled.” Comment: No information 
available to make a judgement. 
Blinding of outcome 
assessment (detection 
bias) 
All outcomes 
Unclear risk omment: Some outcomes did not 
appear to be affected by blinding issues 
because they were objectively 
assessed (complete regression after 
treatment, partial regression after 
treatment, recurrence during followup 
and appearance of new warts during 
treatment) and they were appraised as 
low risk of bias. Other outcomes (any 
local reactions and any systemic 
reactions) were appraised as unclear 
risk of bias 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Low risk Comment: Losses to follow-up were 
less than 20%. 
Selective reporting (reporting 
bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Other bias Low risk Comment: This trial appears to be free 
of other sources of bias 
 
 
Baker 2011 
Methods  
 
Setting: USA, outpatient clinic 
Trial design: Multicentric RCT, parallel three arms 
Funding sources: The trials were supported by Graceway Pharmaceuticals, 
LLC, Bristol, Tennessee 
Ethical issues: “The studies were conducted in compliance with Good Clinical 
Practice guidelines and approved by a central institutional review board. All 
participants provided written informed consent.” 
Participants Inclusion criteria: 
• Women 
• 12 years or older 
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• General good health 
• 2 to 30 EGWs in the vulvar (including mons), inguinal, perineum, and/or perianal 
areas. 
• Minimum total wart area of 10 mm2 
• EGWs were diagnosed clinically; to mimic real world practice, histologic 
conﬁrmation was not required 
Exclusion criteria: 
• Human immunodeﬁcency virus infection 
• Immunosuppression 
• Other genital infections 
• Allergy to imiquimod or cream excipients 
• History of high-risk type HPV infection, high-grade pathology on Papanicolaou 
smear 
• Pregnancy or lactation 
• Imiquimod or HPV vaccination within 1 year, and sinecatechins within 12 weeks, 
cytotoxics, immunomodulators/immunosuppressives, systemic antivirals (excluding 
oral anti herpes agents and oseltamivir), investigational therapies and any 
treatments procedures within the anogenital area within 4 weeks 
Population 
Number of participants: 534 females (212 allocated to imiquimod 2.5%, 216 to 
imiquimod 3.75% and 106 to placebo) 
Mean age: 33.4 years. 
Site of lesions: “The majority of women (54.5%) had warts on 2 or more anogenital 
locations; the most frequently involved locations were vulva (64.8%) and perineal 
(47.9%).” 
Number of lesions: Mean 8.7 
Size of lesions: Mean 166.3 mm2 
Number of participants who received previous treatment: Unclear 
Interventions Total number of intervention groups: Three groups 
Intervention: Imiquimod 2.5%, and imiquimod 3.75% cream applied once daily for 
up to a maximum of 8 weeks 
Control: Vehicle cream applied once daily for up to a maximum of 8 weeks 
Outcomes The trial included a screening visit, an evaluation phase (treatment period of up to 8 
weeks and a no-treatment period of up to 8 weeks) of up to 16 weeks, and an 
observational follow-up phase of up to 12 additional weeks in women with complete 
clearance. 
Participants were assessed every 2 weeks during the evaluation phase. 
Participants with complete clearance of all warts within all anogenital areas entered 
the 12-week observational follow-up period and were assessed every 4 weeks or 
until they had a “recurrence” of any wart (baseline or new) in any anogenital area. 
Spontaneously reported adverse events were collected at each visit 
• Complete regression after treatment (total clearance of the warts) 
• Partial regression after treatment (reduction at least 75% of wart area) 
• Recurrence during follow-up 
• Pain during therapy 
• Any local reactions during (erythema, edema, weeping/exudate, 
ﬂaking/scaling/dryness, scabbing/crusting, and erosion/ulceration) 
Notes Additional information requested from trial authors by e-mail (no answer) 
   
Risk of bias  
Bias 
 
Authors’ judgement 
 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk “Identically appearing study kits were 
prepackaged for each study center 
according to a computer-generated 
randomization schedule using a 1:1:2 
allocation for placebo, imiquimod 2.5%, 
and imiquimod 3.75% cream (3 
MHealth care, Loughborough, UK) and 
a block size of 5.” 
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Allocation concealment 
(selection bias) 
Low risk “The treatment assignment was 
concealed from the participant, the 
investigators and their staff, and the 
clinical research team.” 
Blinding of participants and 
personnel 
(performance bias) 
All outcomes 
Low risk Comment: They used placebo with 
identical appearing in the control group 
to blind trial participants and personnel 
Blinding of outcome 
assessment (detection 
bias) 
All outcomes 
Low risk Comment: Blinding of outcome 
assessors. 
Incomplete outcome data 
(attrition bias) 
All outcomes 
High risk Comment: Discontinuation rate and loss 
to follow-up patients were larger than 
20% (Figure 3.1). They performed per 
protocol analysis 
Selective reporting (reporting 
bias) 
High risk Comment: Some not prespeciﬁed 
subgroups (NCT00674739 and 
NCT00735462) were analyzed, as the 
rate for regression of lesions and the 
risk of recurrence by age, race, gender, 
wart area and number of warts. Finally, 
in spite of the fact that they designed the 
trial to assess the effectiveness and 
safety of the intervention among male 
and female (NCT00674739 and 
NCT00735462), they reported only 
those results of the female included in 
the trial 
Other bias High risk Comment: Funded by industry. 
 
 
Beutner 1998 
Methods  
 
Setting: USA, outpatient clinic 
Trial design: Multicentric RCT, parallel three arms 
Funding sources: The trial was supported by a grant from 3M Pharmaceuticals 
Ethical issues: All patients gave written informed consent before enrollment. 
The protocol and consent forms were reviewed and approved by appropriate 
institutional review boards at each institution 
Participants Inclusion criteria: 
• Otherwise healthy males and females 
• 18 years and older 
• At least 2 but not more than 50 external genital warts 
• Biopsy diagnostic or suggestive of condyloma acuminatum 
• Bidimensional wart area of at least 10 mm2 
• Seronegative for the human immunodeﬁciency virus (HIV) 
• For female patients, not be pregnant or lactating and had to agree to use effective 
birth-control measures 
Exclusion criteria: 
• Genital wart therapy in the 4 weeks prior to treatment initiation 
• For female patients, a pre-trial Pap smear showing a high-grade squamous 
intraepithelial lesion 
Population 
Number of participants: Total 279 (90 allocated to imiquimod 1% (IQ1%), 94 to 
imiquimod 5% (IQ5%) and 95 to placebo) 
Mean age (SD): IQ5%: 30(10), IQ1%: 33(11) Vehicle: 30 (9). 
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Site of lesions: “The primary locations of warts in the female patients were vulva 
(88%) and/or perianal (47%), and in men they were penile (90%) and/or perianal 
(14%).” 
Number of lesions: Median (range). IQ5%: 7 (1 to 47). IQ1%: 8 (1 to 50).Vehicle: 8 
(1 to 45) 
Size of lesions: Median mm2 (range). IQ5%: 137 (2 to 9588). IQ1%: 148 (10 to 
13461). Vehicle: 121 (4 to 2603) 
Number of participants who received previous treatment: 201; (IQ5%: 63, 
IQ1%: 66, Vehicle: 72). 
Interventions Total number of intervention groups: three groups. 
Intervention: Imiquimod 5% cream daily for a maximum of 16 weeks. A second 
group received 1% imiquimod 1% cream daily for a maximum of 16 weeks 
Control: Vehicle cream daily for a maximum of 16 weeks. 
Outcomes During the 8-week treatment period, patients made one initiation visit and seven 
oncea-week interval visits. At these visits, wart evaluations, skin irritation 
assessments and vital sign measurements were recorded. Patients were queried 
regarding adverse events at the site of cream application or adjacent areas. 
Objective evidence of inﬂammation at the site of cream application and at adjacent 
sites was evaluated. Patients who experienced complete clearing of warts during 
the treatment period entered into a treatment free follow-up period of up to 10 
weeks or until recurrence was noted. Patients who had a partial response at the 
end of the 8-week treatment period were evaluated again at week 2 of follow-up to 
determine whether they had achieved complete clearing  
• Complete regression after treatment (total clearance of the warts) 
• Partial regression after treatment (reduction at least 50% of wart area) 
• Recurrence during follow-up  
• Appearance of new warts during treatment 
• Pain during therapy 
• Any local reactions during (erythema, burning, irritation, tenderness, ulceration, 
erosion, itching) 
• Any systemic reactions during therapy (not mentioned and there were no serious 
systemic adverse reactions reported in either group) 
Notes Additional information requested from trial authors by e-mail (no answer) 
   
Risk of bias  
Bias 
 
Authors’ judgement 
 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk “Patients were randomised by study 
centre and gender to receive…” 
Comment: No information available to 
make a judgement. 
Allocation concealment 
(selection bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Blinding of participants and 
personnel 
(performance bias) 
All outcomes 
Unclear risk “double-blind, randomised, parallel-
group study assessed…” Comment: No 
information available to make a 
judgement. 
Blinding of outcome 
assessment (detection 
bias) 
All outcomes 
Unclear risk Comment: Some outcomes did not 
appear to be affected by blinding issues 
because they were objectively 
assessed (complete regression after 
treatment, partial regression after 
treatment, recurrence during followup 
time to complete regression and 
appearance of new warts during 
treatment) and they were appraised as 
low risk of bias. 
Other outcomes (pain, any local 
reactions and any systemic reactions) 
were appraised as unclear risk of bias 
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Incomplete outcome data 
(attrition bias) 
All outcomes 
High risk “Of the 279 patients, 72 (26%) did not 
complete treatment (25 in the 5% 
imiquimod cream group, 19 in the 1% 
imiquimod cream group, and 28 in the 
vehicle group)” 
Comment: Number of withdrawals is 
large enough to inﬂuence effect 
estimates. Per protocol analysis 
Selective reporting (reporting 
bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Other bias High risk Comment: Funded by industry. 
 
 
Beutner 1998a 
Methods  
 
Setting: USA, outpatient clinic 
Trial design: Multicentric randomized clinical trial, parallel two arms 
Funding sources reported: Yes, the trial was supported by 3M Pharmaceuticals. 
Ethical issues: Informed consent and review board per center. 
Participants Inclusion criteria: 
• HIV seronegative 
• Neither lactating nor pregnant 
• More than 18 years old 
Exclusion criteria: 
• Women with vaginal warts or low- or high-grade cervical squamous intraepithelial 
Population 
Number of participants: Total 108 (51 allocated to imiquimod and 57 to placebo) 
Mean age: 29 years for imiquimod, 30 years for vehicle. 
Site of lesions: genital: men (predominantly 91% on the shaft of the penis) and 
women (vulva, perineal, and perianal areas, the mons pubis and thigh). Some 
subject had warts at multiple sites 
Number of participants who received previous treatment: 74/108 (Imiquimod 
35/51, Vehicle 39/57). 
Interventions Total number of intervention groups: Two groups. 
Intervention: Imiquimod 5% three times weekly for up to 8 weeks. 
Control: Physically indistinguishable cream three times per week for up to 8 weeks 
Outcomes Patients were evaluated weekly for the ﬁrst 4 weeks and every 2 weeks there after 
for the remainder of the 16-week treatment period as well as during the 12-week 
follow-up period. A detailed wart assessment, including photographs, 
measurements, counts, and location, was completed before the trial treatment was 
initiated and at each evaluation visit. New warts that developed during the treatment 
period were treated with trial medication and were followed separately from the 
baseline target warts. Both the patient and trial personnel assessed local skin 
reactions at the treatment sites. All patients were asked about adverse experiences 
at each evaluation visit 
• Complete regression after treatment (total clearance of the warts) 
• Partial regression after treatment (reduction at least 50% of wart area) 
• Recurrence during follow-up (from 0 to six months) 
• Appearance of new warts during treatment 
• Local reactions during therapy (erythema, excoriation or ﬂaking, erosion, edema, 
scabbing, induration, ulceration, vesicles) 
Notes Additional information requested from trial authors by e-mail (no answer) 
   
Risk of bias  
Bias 
 
Authors’ judgement 
 
Support for judgement 
Random sequence 
generation (selection 
Unclear risk “This study was a double-blind, 
randomised, placebo-controlled, 
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bias) parallel design conducted at three 
centres.” Comment: No information 
available to make a judgement. 
Allocation concealment 
(selection bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Blinding of participants and 
personnel 
(performance bias) 
All outcomes 
Unclear risk Comment: Blinding was described as 
“double-blinded” and did not specify 
who. No information available to make a 
judgement 
Blinding of outcome 
assessment (detection 
bias) 
All outcomes 
Unclear risk Comment: Some outcomes did not 
appear to be affected by blinding issues 
because they were objectively 
assessed (complete regression after 
treatment, partial regression after 
treatment, recurrence during followup, 
time to complete regression and 
appearance of new warts during 
treatment) and they were appraised as 
low risk of bias. 
Other outcomes (pain, any local 
reactions and any systemic reactions) 
were appraised as unclear risk of bias 
Incomplete outcome data 
(attrition bias) 
All outcomes 
High risk Comment: Intention-to-treat analysis 
was performed only for one out of seven 
outcomes (complete clearance) 
Selective reporting (reporting 
bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Other bias High risk Comment: Funded by industry. 
 
 
Edwards 1998 
Methods  
 
Setting: USA and Canada, outpatient clinic 
Trial design: Multicentric randomized clinical trial, parallel, three arms 
Funding sources: The trial was supported by 3M pharmaceuticals. 
Ethical issues: Ethical board and sign consent. 
Participants Inclusion criteria: 
• Healthy men and women 
• 18 years or older 
• 2 to 50 external lesions, the total wart area was no less than 10 mm 
• Biopsy (diagnostic or suggestive) no dysplasia 
• No treatment 4 weeks before enrollment 
Exclusion criteria:  
• High-grade squamous intraepithelial lesions 
• Patients immunosuppressed 
• Pregnant or lactating women 
• Chemical or alcohol dependency 
• Skin disease 
• Any local drug 2 weeks before enrollment 
Population 
Number of participants: Total 311 (102 allocated to imiquimod 1%, 109 to 
imiquimod 5% and 100 to placebo) 
Mean age (SD): IQ5%: 32 (12). IQ1%: 30 (10). Vehicle: 31 (10). 
Size of lesions: Median mm2 (range). IQ5%: 69 (8 to 5525). IQ1%: 74 (10 to 4271). 
Vehicle: 77 (7 to 5000) 
Number of participants who received previous treatment: Unclear. 
Interventions Total number of intervention groups: Three groups. 
Intervention: Imiquimod 5% or 1%. 3 times each week until complete clearance or 
for a maximum of 16 weeks 
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Control: Patients self-applied vehicle cream 3 times until complete clearance or for 
a maximum of 16 weeks 
Outcomes During the ﬁrst examination, regional lesions were determined and mapped, and 
photographed. During the treatment phase of the trial, the patients were seen 
weekly for 2 weeks and the biweekly until their warts cleared of the remainder of the 
16 week treatment period. During each visit, patient diaries were checked and 
patients were questioned for adverse reactions. Warts were measured and 
photographed and the area was examined for signs and symptoms of local 
inﬂammation 
• Complete regression after treatment (total clearance of the warts) 
• Partial regression after treatment (reduction at least 50% of wart area) 
• Recurrence during follow-up 
• Appearance of new warts during treatment 
• Any local reactions during (erythema, erosion, excoriation or ﬂaking, edema, 
scabbing, induration) 
Notes Additional information requested from trial authors by e-mail (no answer) 
   
Risk of bias  
Bias 
 
Authors’ judgement 
 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk “…patients were randomised to use 1 of 
3 treatments…” 
Comment: No information available to 
make a judgement. 
Allocation concealment 
(selection bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Blinding of participants and 
personnel 
(performance bias) 
All outcomes 
Unclear risk “Randomized, double-blind, placebo-
controlled comparison…” 
Comment: No information available to 
make a judgement. 
Blinding of outcome 
assessment (detection 
bias) 
All outcomes 
Unclear risk Comment: Some outcomes did not 
appear to be affected by blinding issues 
because they were objectively 
assessed (complete regression after 
treatment, partial regression after 
treatment, recurrence during followup 
and appearance of new warts during 
treatment) and they were appraised as 
low risk of bias. Other outcomes (any 
local reactions and any systemic 
reactions) were appraised as unclear 
risk of bias 
Incomplete outcome data 
(attrition bias) 
All outcomes 
High risk “Seventy-seven patients discontinued 
use of medication during the study, and 
the discontinuation rate was similar for 
each group” 
Comment: 25% withdrawals 
Selective reporting (reporting 
bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Other bias High risk Comment: Funded by industry. 
 
 
Komericki 2011 
Methods  
 
Setting: Austria, outpatient clinic 
Trial design: Single center, randomized clinical trial. Parallel two arms 
Funding sources: The trial was not funded by any drug manufacturer 
Ethical issues: Informed consent 
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Participants Inclusion criteria: 
• Never treated for AGW 
Exclusion criteria: 
• Age below 18 years 
• Immunosuppression 
• Pregnancy 
• Breast-feeding 
• Involvement of the anal canal 
• Severe disease requiring surgery 
Population 
Number of participants: Total 45 (20 allocated to imiquimod and 25 to 
podophyllotoxin) 
Mean 
age: 30 years 
Site of lesions: Genital 60%; anal 20% and anogenital 20%  
Number of participants who received previous treatment: Not mentioned 
Interventions Total number of intervention groups: Two groups. 
Intervention: Imiquimod 5%, three times per week until complete clearance or up 
to 16 weeks 
Control: Podophyllotoxin 0,5%, two times on three consecutive days per week until 
complete clearance or up to 4 weeks 
Outcomes Efﬁcacy (primary endpoint) was assessed at the end of treatment, 5 weeks after the 
start of podophyllotoxin and 16 weeks after the start of imiquimod. Side effects 
(secondary endpoint) were assessed at each check up, 2 weeks after the start and 
at the end of podophyllotoxin treatment; and 4, 8, 12 and 16 weeks after the start of 
imiquimod therapy 
• Complete regression after treatment (total clearance of the warts) 
• Any local reactions during therapy (erythema/inﬂammation, erosions, 
erythema/inﬂammation plus erosions) 
Notes No additional information requested from trial authors. 
   
Risk of bias  
Bias 
 
Authors’ judgement 
 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk “Allocation to treatment groups was 
done according to a ranking, which was 
created by block randomisation. Each 
block contained 4 items (2X imiquimod 
and 2X podophyllotoxin) to assure a 
balanced design with equal group sizes” 
Comment: Probably done. Lowrisk of 
bias. 
Allocation concealment 
(selection bias) 
High risk Comment: The trial was an open label 
trial and realized a block randomization 
process been possible that the 
intervention allocation could have been 
foreseen in advance making selection 
bias at entry likely 
Blinding of participants and 
personnel 
(performance bias) 
All outcomes 
High risk The trial was an open label trial and the 
authors mentioned during the trial “A 
potential bias might result from lack of 
blinding patients and clinicians as to the 
treatment assignment” 
Blinding of outcome 
assessment (detection 
bias) 
All outcomes 
High risk Comment: Unblinded to personnel and 
trial participants making likely the risk 
for performance bias. The outcomes 
complete regression, recurrence during 
followup and appearance of new warts 
during treatment were appraised as low 
risk for detection bias because were 
66 Imiquimod for anogenital warts in non-immunocompromised 
adults (Review) 
 
outcomes objectively assessed and we 
judge that the lack of blinding of the 
outcome assessor is unlikely to affect 
the results. On the other hand, the 
outcomes pain, local reaction and 
systemic reaction during therapy, were 
assessed subjectively and we judge 
that the lack blinding of the outcome 
assessors from knowledge of which 
intervention a participant received make 
possible the detection bias 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Low risk “Six patients were lost to follow-up, 5 in 
the imiquimod, and 1 in the 
podophyllotoxin group” 
Comment: Missing outcome data 
balanced across groups and less than 
20% of missing data 
Selective reporting (reporting 
bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Other bias Low risk Comment: This trial appears to be free 
of other sources of bias 
 
 
Padhiar 2006 
Methods  
 
Setting: India, outpatient clinic 
Trial design: Single center randomized clinical trial, parallel two arms 
Funding sources: Not reported 
Ethical issues: Not stated 
Participants Inclusion criteria: 
• Clinical diagnosis of AGW 
• At least two but not more than 50 warts 
Exclusion criteria: 
• HIV 
Population 
Number of participants: Total 60 (30 allocated to imiquimod and 30 to placebo) 
from 26 to 35 years old 
Site of lesions: In males were located predominantly on penis and in females, 
were located on vulva (50%) followed by 16.6% in perianal area 
Number of lesions: Imiquimod 5%: 105 total warts. Podophyllin 20%: 90 total 
warts 
Size of lesions: Imiquimod 5%: 2100 mm2 and podophyllin 20%: 2500 mm. 
Number of participants who received previous treatment: Not mentioned. 
Interventions Total number of intervention groups: Two groups. 
Intervention: Imiquimod 5% cream three times each week until all baseline warts 
disappeared or for 16 weeks  
Control: Podophyllin 20% once in a week for maximum up to 6 weeks. 
Outcomes During the ﬁrst examination, regional lesions were determined and mapped, and the 
localizations and periods of the lesions were recorded. During the duration of the 
therapy, the lesions were re-assessed re-mapped and the side effects of the drug 
were investigated. 
When warts were removed, the treatment was interrupted, and the patients were 
followed-up. At the end of the therapy patients were assessed for recurrences for a 
period of six months by quarterly visits 
• Complete regression after treatment (total clearance of the warts) 
• Recurrence during follow-up from 0 to 6 months 
• Any local reactions during therapy (erythema, edema, induration, ulceration, 
itching and vesiculation) 
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• Any systemic reactions during therapy (headache, diarrhea, inﬂuenza-like 
symptoms) 
Notes Additional information requested from the trial authors by e-mail (no answer) 
   
Risk of bias  
Bias 
 
Authors’ judgement 
 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Unclear risk “Patients were randomised to receive 
…” 
Comment: No information available to 
make a judgement. 
Allocation concealment 
(selection bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Blinding of participants and 
personnel 
(performance bias) 
All outcomes 
Unclear risk Comment: No information available to 
make a judgement. 
Blinding of outcome 
assessment (detection 
bias) 
All outcomes 
Unclear risk Comment: Some outcomes did not 
appear to be affected by blinding issues 
because they were objectively 
assessed (complete regression after 
treatment, recurrence during follow-up) 
and they were appraised as low risk of 
bias. Other outcomes (any local 
reactions and any systemic reactions) 
were appraised as unclear risk of bias 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Unclear risk Comment: The authors did not reported 
the attrition and exclusions in sufﬁcient 
detail to allow an assessment 
Selective reporting (reporting 
bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Other bias Low risk Comment: This trial appears to be free 
of other sources of bias 
 
 
Schofer 2006 
Methods  
 
Setting: Germany, outpatient clinic 
Trial design: Multicentric randomized clinical trial, parallel, 3 arms 
Funding sources: The trial was supported by 3M Medica, Neuss, Germany 
Ethical issues: The trial was approved by the local ethics committees. Informed 
consent 
Participants Inclusion criteria: 
• Participants of both gender over 18 years 
• External AGW with maximum extension area of 2000 mm2 
• Maximum height of single AGW less than 1 cm 
Exclusion criteria: 
• Imiquimod 5% cream within the previous 6 months 
• Any other AGW therapy within 4 weeks prior 
• Inflammatory skin conditions within the target area 
• Autoimmune diseases or immunosuppression 
• Pregnant or lactating females 
Population 
Number of participants: Total 358 (100 allocated to ablation alone, 155 to 
imiquimod and 103 to ablation followed by imiquimod) 
Mean age: 33.1 years (range 18 to 73). 
Site of lesions: “The most common location of genital warts was the foreskin/glans 
penis and the penis shaft in males and the vulva in females” 
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Size of lesions: Mean mm2 (range): Ablation 142.2 mm2 (4 to 1960), imiquimod: 
105. 5 mm2 (1 to 1912), ablation + imiquimod: 180.3mm2 (2 to 1354). 
Number of participants who received previous treatment: 153 (Ablation: 36, 
imiquimod: 68, and ablation + imiquimod: 49 participants) 
Interventions Total number of intervention groups: Three. Ablation, imiquimod, and ablation + 
imiquimod. 
Intervention: Imiquimod 5%3 times peer week before bedtime until complete 
clearance or for a maximum of 16 weeks 
Comparison: The subjects were treated depending on which ablative method was 
practiced by the investigator: electrocautery, liquid nitrogen, laser therapy or 
surgical removal. 
The procedure could be repeated over a period of 4 weeks until all visible AGW 
were removed. The third group received ablation plus imiquimod. The participants 
had an ablative procedure and after complete clearance and wound healing, started 
an adjuvant treatment with imiquimod 5% 
Outcomes The trial consisted of a treatment phase and a 6-month follow-up period. The 
primary efﬁcacy parameter was the observed sustained clearance at month three of 
the treatmentfree follow-up period. Additionally, subjects were assessed after 4 
weeks and at 6 months post-treatment for sustained clearance/recurrences. The 
investigators assessed the safety of the imiquimod treatments at each control visit 
by documenting the presence of local skin reactions. Subjects reported any 
symptoms like itching, burning or pain 
• Complete regression after treatment (total clearance of the warts) 
• Recurrence during follow-up from 0 to 6 months 
• Local reactions (erythema, edema, induration, vesicles, erosion, ulceration, ﬂaking 
or scabbing) 
Notes Additional information requested from the trial authors by e-mail (no answer) 
   
Risk of bias  
Bias 
 
Authors’ judgement 
 
Support for judgement 
Random sequence 
generation (selection 
bias) 
Low risk Comment: The trial adequately reported 
the random method generation by using 
the RPAS 3 program, Version 1.52, a 
part of the EQUILA software package of 
Episys Ltd 
Allocation concealment 
(selection bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Blinding of participants and 
personnel 
(performance bias) 
All outcomes 
High risk Comment: This trial was an open label 
trial. 
Blinding of outcome 
assessment (detection 
bias) 
All outcomes 
High risk Comment: Unblinded to personnel and 
trial participants making likely the risk 
for performance bias. The outcomes 
complete regression, recurrence during 
followup and appearance of new warts 
during treatment were appraised as low 
risk for detection bias because were 
outcomes objectively assessed and we 
judge that the lack of blinding of the 
outcome assessor is unlikely to affect 
the results. On the other hand, the 
outcomes pain, local reaction and 
systemic reaction during therapy, were 
assessed subjectively and we judge 
that the lack blinding of the outcome 
assessors from knowledge of which 
 69 
 
intervention a participant received make 
possible the detection bias 
Incomplete outcome data 
(attrition bias) 
All outcomes 
High risk Comment: Per protocol analysis. 
Selective reporting (reporting 
bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Other bias High risk Comment: Funded by industry. 
 
 
Stefanaki 2008 
Methods  
 
Setting: Greece, outpatient clinic 
Trial design: Single center randomized clinical trial, parallel two arms 
Funding sources: Not reported 
Ethical issues: The trial protocol was approved by the Institutional Review 
Board. Informed consent was obtained 
Participants Inclusion criteria: 
• Immunocompetent male patients 
• First diagnosed with external genital and perianal warts 
• No patient had undergone any type of treatment for AGW prior to enrollment 
Exclusion criteria: 
• Bowenoid papulosis 
• Severe medical condition (haematological, hepatic-hepatitis B or C, neurological, 
renal, endocrine, collagen and gastrointestinal). 
• Drug or alcohol dependency 
Population 
Number of participants: 80 males (35 allocated to imiquimod and 45 to 
cryotherapy). Mean age (SD). IQ5%: 31.8 (10.8). Cryotherapy: 30.7 (12.2) 
Site of lesions: IQ5%: genital 26 (74.3%), anal 7 (20%) and anogenital 2 (5.7%) 
Cryotherapy: genital 39 (86.7%), anal 3 (6.7%) and anogenital 3 (6.7%) 
Number of lesions: IQ5%: 1 to 10 lesions (57%), > 10 (43%). Cryotherapy: 1 to 10 
lesions (65%). > 10 (35%) 
Shape of lesions: IQ5%: Penduculated 20 (57.1%). Papular 3 (8.6%). Criotherapy: 
Penduculated: 9 (20%). Papular: 18 (40%) 
Size of lesions: IQ5%: = 2 cm2: 21 (60%). > 2 cm2: 14 (40%). Cryotherapy: = 2 cm 
: 19 (42%). > 2 cm2: 26 (57.8%). 
Number of participants who received previous treatment: None 
Interventions Total number of intervention groups: 2 groups. 
Intervention: Imiquimod 5% cream three times a week for twelve weeks. 
Control: Cryotherapy once in three weeks for three consecutive sessions 
Outcomes At the initial visit prior to treatment, the baseline warts were photographed and 
measured and the exact number of warts, their location, morphology, color and 
duration were recorded. Follow-up appointments were arranged every month for the 
ﬁrst three months and after six and 12 months, or in between whenever the patients 
noticed any signs of recurrence. During the treatment period, at each visit, warts 
were measured and photographed and any local or adverse systemic reactions 
were documented 
• Complete regression after treatment (total clearance of the warts) 
• Recurrence during follow-up from 0 to 6 months 
• Pain during therapy 
• Any local reactions during therapy (erythema, oedema, erosions, ulceration and 
fever) 
• Any systemic reactions during therapy (fever) 
Notes Additional information requested from the trial authors by e-mail (no answer) 
   
Risk of bias  
Bias 
 
Authors’ judgement 
 
Support for judgement 
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Random sequence 
generation (selection 
bias) 
Unclear risk “Patients were randomised to receive 
either…” 
Comment: No information available to 
make a judgement. 
Allocation concealment 
(selection bias) 
Unclear risk Comment: No information available to 
make a judgement. 
Blinding of participants and 
personnel 
(performance bias) 
All outcomes 
High risk Comment: This trial was a open label 
trial. 
Blinding of outcome 
assessment (detection 
bias) 
All outcomes 
High risk Comment: Unblinded to personnel and 
trial participants making likely the risk 
for performance bias. The outcomes 
complete regression, recurrence during 
followup and appearance of new warts 
during treatment were appraised as low 
risk for detection bias because these 
outcomes were objectively assessed 
and we judged that the lack of blinding 
of the outcome assessor is unlikely to 
affect the results. On the other hand, the 
outcomes pain, local reaction and 
systemic reaction during therapy, were 
assessed subjectively and we judged 
that the lack blinding of the outcome 
assessors from knowledge of which 
intervention a participant received make 
possible the detection bias 
Incomplete outcome data 
(attrition bias) 
All outcomes 
High risk “15 patients from the imiquimod group 
(30%) and 25 patients from the 
cryotherapy (64,2%) group were either 
lost from follow-up or did not provide 
analyzable data” 
Comment: Substantial numbers of 
missing and per protocol analysis 
Selective reporting (reporting 
bias) 
High risk Comment: During the materials and 
methods sections, the authors did not 
mention time to complete clearance and 
partial clearance as primary or 
secondary outcomes, but they reported 
this in the results section 
Other bias Low risk Comment: This trial appears to be free 
of other sources of bias 
 
 
Tyring 1998 
Methods  
 
Setting: No information about country or setting 
Trial design: Randomized clinical trial, parallel, two arms 
Funding sources: The trial was supported by 3M Pharmaceuticals 
Ethical issues: Informed consent was obtained from each patient 
Participants Inclusion criteria: 
• 18 ys old or older 
• Histologically conﬁrmed diagnosis 
• Patients had to have at least ten but no more than 50 warts prior to pre-trial biopsy 
Exclusion criteria: 
• HIV 
• High-grade cervical intraepithelial lesions 
• Previously treated with imiquimod or, within 4 weeks of the trial, received IFN, 
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an IFN-inducer, an immunomodulator, oral or topical antiviral drugs, cytotoxic or 
investigational drugs, or chemical and/or surgical wart therapy 
• Any topical non-wart therapy to the wart site, or oral or inhaled corticosteroids 
within 2 weeks of the trial were also ineligible 
Population 
Number of participants: 22 (16 allocated to imiquimod and 6 to placebo). 
Age of participants: No data 
Site of lesions: No data 
Number of participants who received previous treatment: Unclear. 
Interventions Total number of intervention groups: Two groups. 
Intervention: Imiquimod 5% cream three times per week for a maximum of 16 
weeks 
Control: Vehicle cream three times per week for a maximum of 16 weeks 
Outcomes Patients were seen every 2 weeks until their target warts cleared or up through 16 
weeks of treatment, whichever occurred ﬁrst 
• Complete regression after treatment (total clearance of the warts) 
• Partial regression after treatment (reduction at least 75% of wart area) 
Notes Additional information requested from the trial authors by e-mail (no answer) 
   
Risk of bias  
Bias 
 
Authors’ judgement 
 
Support for judgement 
Random sequence 
generation (selection 
bias) 
High risk “Patients were stratiﬁed by gender and 
randomized to imiquimod cream 5% or 
vehicle in a 4:1 ratio” 
Comment: The random sequence 
generation was broken because two 
lost participants were directly replaced, 
making the selection bias likely at entry 
Allocation concealment 
(selection bias) 
High risk Comment: The random sequence 
generation was broken because two 
lost participants were directly replaced, 
making the selection bias likely at entry 
Blinding of participants and 
personnel 
(performance bias) 
All outcomes 
Unclear risk Comment: No information available to 
make a judgement. 
Blinding of outcome 
assessment (detection 
bias) 
All outcomes 
Unclear risk Comment: Some outcomes did not 
appear to be affected by blinding issues 
because they were objectively 
assessed (complete regression after 
treatment, partial regression after 
treatment) and they were appraised as 
low risk of bias. Other outcome (any 
systemic reactions) was appraised as 
unclear risk of bias 
Incomplete outcome data 
(attrition bias) 
All outcomes 
Low risk Comment: Losses to follow-up were 
less than 20%. 
Selective reporting (reporting 
bias) 
High risk Comment: During background section, 
the authors mentioned systemic 
reaction but not reported during 
outcome section 
Other bias High risk Comment: Funded by industry. 
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Tabla 2: Characteistics of excluded studies. 
Study  Reason for exclusion 
Alam 2001 Not a RCT. 
Ankerst 2009  Not a RCT. 
Arany 1999  Duplicate from Tyring 1998. 
Baker 2010  Duplicate from Baker 2011. 
Beutner 1995  Duplicate from Beutner 1998 and Edwards 1998. 
Beutner 1998b  Duplicate from Beutner 1998 and Edwards 1998. 
Buck 2002  Not a RCT. 
Carey 2004  Not a RCT. 
Carrasco 2002  No intervention: use of imiquimod before all intervention groups 
Castellsague 2000  Not a RCT. 
Chopra 1997  Duplicate from Tyring 1998. 
Como 2010 Not a RCT. 
Corona 2002  Not a RCT. 
Dall’oglio 2012  Not a RCT. 
Desai 2006  Not a RCT. 
Edwards 1995 Duplicate from Edwards 1998. 
Ferenczy 1998  Duplicate from Edwards 1998. 
Ferris 2010  Duplicate from Baker 2011. 
Fife 2001  Not comparison: all the intervention groups included imiquimod 
Garland 2001  Not a RCT. 
Garland 2006  Not comparison: all the intervention groups included imiquimod 
Gibbs 2006 Not a RCT. 
Gollnick 2001  Not a RCT. 
Gotovtseva 2008  Not a RCT. 
Jaffary 2007 Not a RCT. 
Jappe 1998  Not a RCT. 
Kwok 2012  Not a RCT. 
Lafuma 2003  Not a RCT. 
Langley 2010  Not a RCT. 
Maw 2002 Not a RCT. 
Maw 2004 Not a RCT. 
Meltzer 2009 Not a RCT. 
Miller 1999a Not a RCT. 
Mistrangelo 2010  No intervention: not imiquimod. 
Moore 2001 Not a RCT. 
NCT00114023 Not a RCT. 
NCT00189293  No intervention: use of imiquimod before all intervention groups 
NCT00674739  Duplicate from Baker 2011. 
NCT00735462  Duplicate from Baker 2011. 
NCT00941811 Not a RCT. 
NCT00979550  No intervention: not imiquimod alone. 
O’Mahony 2001 Not a RCT. 
Owens 1999  Duplicate from Edwards 1998. 
Puri 2009  Not a RCT. 
Sauder 2003a  Duplicate from Edwards 1998. 
Sauder 2003b  No intervention: not imiquimod. 
Schöfer 2007  Not a RCT. 
Syed 1998  Risk of fraud. 
Syed 2000 Risk of fraud. 
Syed 2002  Risk of fraud. 
Trofatter 1998 Not a RCT. 
Trofatter 2002  No comparison: all the intervention groups included imiquimod 
Tuncel 2005  No comparison: all the intervention groups included imiquimod 
Tyring 1997  Duplicate from Beutner 1998 and Edwards 1998. 
Walczak 2009 Not a RCT. 
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Walczak 2009a Not a RCT. 
Wang 2007 Not a RCT: cross-over design 
Weinberg 1997 Not a RCT. 
Williams 2003 Not a RCT. 
Yan 2006  Not a RCT. 
 
Tabla 3: Characteistics of studies awaiting assessment. 
 
CTRI/2009/091/000055 
Methods  
 
RCT 
Participants Patients with AGW, with surface area of warts 10 mm2 or more, healthy adults, > 12 
years of age, without treatment during past 4 weeks. 89 patients (71 male and 18 
female) 
Interventions Mycobacterium vaccine (maximum up to 0.1 mL in one session). 5%imiquimod 
cream 3 times a week for 16 weeks. Follow-up period of up to 16 weeks 
Outcomes Complete clearance, adverse events. 
 
Ferenczy 1999   
Methods  
 
Two multicenter, randomized, vehicle-controlled, double-blind clinical trials 
Participants Female patients with AGW. 119 female were to imiquimod group, 105 female were 
to vehicle group 
Interventions Imiquimod 5% or vehicle cream, three times per week for up to 16 weeks or until 
wart clearance, follow-up period of up to 12 weeks 
Outcomes Complete clearance, partial clearance, adverse events. 
 
Nelson 2014 
Methods  
 
Two identical multicenter, randomized, double-blind, placebo controlled studies 
Participants Subjects (12 years old) with 2 to 30 external genital warts and total wart area of 10 
mm2. 981 subjects were enrolled (470 subjects Study 1 and 511 subjects Study 2) 
Interventions Imiquimod 3.75%, imiquimod 2.5%, or vehicle cream (2:2:1) once daily until 
complete clearance or a maximum of 8 weeks, follow-up period of up to 12 weeks 
Outcomes Complete clearance, partial clearance, time to clearance, visual assessment of local 
skin reaction 
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C. Appendix 3: Data and analyses9 
Comparison 1:    Imiquimod versus placebo 
 
 
 
 
 
 
 
 
 
 
                                               
 
9 This document has been published elsewhere as form of the review entitled Imiquimod for 
anogenital warts in non-immunocompromised adults, published in The Cochrane Library 2014, Issue 
11; available on: http://www.thecochranelibrary.com 
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Comparison 2: Imiquimod versus any other patient-applied treatment. 
 
Comparison 3: Imiquimod versus any other provider-administered treatment. 
 
Comparison 4: Imiquimod versus placebo (outcome: complete regression after 
treatment). 
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Comparison 5: Imiquimod versus placebo (outcome: complete regression after 
treatment). 
 
Comparison 6: Imiquimod versus placebo (outcome: complete regression after 
treatment). 
 
Comparison 7: Imiquimod versus placebo (outcome: complete regression after 
treatment). 
 
Comparison 8: Imiquimod versus placebo (outcome: complete regression after 
treatment). 
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Comparison 9: Imiquimod versus placebo (outcome: partial regression after 
treatment). 
 
Comparison 10: Imiquimod versus placebo (outcome: partial regression after 
treatment). 
 
Comparison 11: Imiquimod versus placebo (outcome: partial regression after 
treatment). 
 
Comparison 12: Imiquimod versus placebo (outcome: partial regression after 
treatment). 
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Comparison 13: Imiquimod versus placebo (outcome: partial regression after 
treatment). 
 
Analysis 14.1: Comparison 1 Imiquimod versus placebo, Outcome 1 Complete 
regression after treatment. 
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Analysis 15.2: Comparison 1 Imiquimod versus placebo, Outcome 2 Partial 
regression after treatment. 
 
Analysis 16.17: Comparison 1 Imiquimod versus placebo, Outcome 3 Recurrence 
during follow-up from 0 to 6 months. 
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Analysis 18.19: Comparison 1 Imiquimod versus placebo, Outcome 4 Appearance 
of new warts during treatment. 
 
Analysis 20.21: Comparison 1 Imiquimod versus placebo, Outcome 5 Pain during 
therapy. 
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Analysis 22.23: Comparison 1 Imiquimod versus placebo, Outcome 6 Any local 
reactions during therapy. 
 
Analysis 24.25: Comparison 1 Imiquimod versus placebo, Outcome 7 Any systemic 
reactions during therapy. 
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Analysis 26.1: Comparison 2 Imiquimod versus any other patient-applied 
treatment, Outcome 1 Complete regression after treatment. 
 
Analysis 27.2: Comparison 2 Imiquimod versus any other patient-applied 
treatment, Outcome 2 Partial regression after treatment. 
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Analysis 28.3: Comparison 2 Imiquimod versus any other patient-applied 
treatment, Outcome 3 Recurrence during follow-up from 0 to 6 months. 
 
Analysis 29.4: Comparison 2 Imiquimod versus any other patient-applied 
treatment, Outcome 4 Any local reactions during therapy. 
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Analysis 30.5: Comparison 2 Imiquimod versus any other patient-applied 
treatment, Outcome 5 Any systemic reactions during therapy. 
 
Analysis 31: Comparison 3 Imiquimod versus any other provider-administered 
treatment, Outcome 1 Complete regression after treatment. 
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Analysis 32: Comparison 3 Imiquimod versus any other provider-administered 
treatment, Outcome 2 Recurrence during follow-up from 0 to 6 months. 
 
Analysis 33: Comparison 3 Imiquimod versus any other provider-administered 
treatment, Outcome 3 Recurrence during follow-up from 6 to 12 months. 
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Analysis 34: Comparison 3 Imiquimod versus any other provider-administered 
treatment, Outcome 4 Pain during therapy. 
 
Analysis 35: Comparison 3 Imiquimod versus any other provider-administered 
treatment, Outcome 5 Any local reactions during therapy. 
 
 
 
 
 
 
 87 
 
Analysis 36.1: Comparison 4 Imiquimod versus placebo (outcome: complete 
regression after treatment), Outcome 1 Concentration of imiquimod. 
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Analysis 37: Comparison 5 Imiquimod versus placebo (outcome: complete 
regression after treatment), Outcome 1 Duration of therapy. 
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Analysis 38: Comparison 6 Imiquimod versus placebo (outcome: complete 
regression after treatment), Outcome 1 Times per week. 
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Analysis 39: Comparison 7 Imiquimod versus placebo (outcome: complete 
regression after treatment), Outcome 1 Lesion site. 
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Analysis 40: Comparison 8 Imiquimod versus placebo (outcome: complete 
regression after treatment), Outcome 1 Sex of the patient. 
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Analysis 41: Comparison 9 Imiquimod versus placebo (outcome: partial 
regression after treatment), Outcome 1 Concentration of imiquimod. 
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Analysis 42: Comparison 10 Imiquimod versus placebo (outcome: partial 
regression after treatment), Outcome 1 Duration of therapy. 
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Analysis 43: Comparison 11 Imiquimod versus placebo (outcome: partial 
regression after treatment), Outcome 1 Times per week. 
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Analysis 44.1: Comparison 12 Imiquimod versus placebo (outcome: partial 
regression after treatment), Outcome 1 Lesion site. 
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Analysis 45.1: Comparison 13 Imiquimod versus placebo (outcome: partial 
regression after treatment), Outcome 1 Sex of the patient. 
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D. Appendix 4: Electronic search 
strategies10 
MEDLINE and CENTRAL (Ovid platform) 
1 exp Condylomata Acuminata/ 
2 condyl$.tw. 
3 acuminat$.tw. 
4 accuminat$.tw. 
5 exp Warts/ 
6 wart$.tw. 
7 verruca$.tw. 
8 papillomavirus$.tw. 
9 (papilloma adj5 virus).tw. 
10 hpv.tw. 
11 or/1-10 
12 imiquimod.tw. 
13 randomised controlled trial.pt. 
14 controlled clinical trial.pt. 
15 randomized.ab. 
16 placebo.ab. 
17 clinical trials as topic.sh. 
18 randomly.ab. 
19 trial.ti. 
20 or/13-19 
21 exp animals/ not humans.sh. 
22 20 not 21 
23 11 and 12 and 22 
Note: the CENTRAL search strategy does not include the terms #13 to #22. 
                                               
 
10 This document has been published elsewhere as form of the review entitled Imiquimod for 
anogenital warts in non-immunocompromised adults, published in The Cochrane Library 2014, Issue 
11; available on: http://www.thecochranelibrary.com 
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EMBASE.com 
1 ’condyloma acuminatum’/exp 
2 condyl*:ab,ti 
3 acuminat*:ab,ti 
4 accuminat*:ab,ti 
5 ’condyloma latum’/exp 
6 ’verruca vulgaris’/exp 
7 verruca*:ab,ti 
8 wart*:ab,ti 
9 ’wart virus’/exp 
10 hpv:ab,ti 
11 (papilloma NEAR/5 virus):ab,ti 
12 papillomavirus*:ab,ti 
13 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 
14 ’imiquimod’/exp 
15 imiquimod:ab,ti 
16 14 OR 15 
17 ’randomised controlled trial’/exp 
18 ’single blind procedure’/exp 
19 ’double blind procedure’/exp 
20 ’crossover procedure’/exp 
21 17 OR 18 OR 19 OR 20 
22 random*:ab,ti 
23 placebo*:ab,ti 
24 allocat*:ab,ti 
25 crossover*:ab,ti 
26 ’cross over’:ab,ti 
27 trial:ti 
28 (doubl* NEXT/1 blind*):ab,ti 
29 22 OR 23 OR 24 OR 25 OR 26 OR 27 OR 28 
30 21 OR 29 
31 ’animal’/de 
32 ’animal experiment’/de 
33 ’nonhuman’/de 
34 31 OR 32 OR 33 
35 ’human’/de 
36 34 AND 35 
37 34 NOT 36 
38 30 NOT 37 
39 13 AND 16 AND 38 AND [embase]/lim 
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Cochrane Sexually Transmitted Infections Group Specialized Register 
Using the terms “imiquimod” and “wart” in title, abstract and keywords. 
 
Other sources search strategies 
 
Web of Science 
Topic CONTAINS: ((“condylomata acuminata”) OR (condyl* OR acuminat* OR accuminat*) 
OR (“warts”) OR (wart* OR verruca*) OR (papillomavirus* OR hpv) OR (papilloma NEAR/5 
virus)) AND (imiquimod) 
 
Clinical Trials 
Search terms: Imiquimod 
 
International Clinical Trials Registry Platform 
Keywords CONTAINS: Imiquimod 
 
Open SIGLE 
Keywords CONTAINS: (condyloma) OR (warts) OR (veruucas) OR (acuminate) OR 
(accuminata) OR (acuminatum) OR (papillomavirus) OR (papilloma NEAR/5 virus) OR 
(hpv) AND (imiquimod) discipline:(06E - Medicine) 
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